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ABSTRACT 
Amyotrophic Lateral Sclerosis (ALS) is a late onset, fatal, neurodegenerative disorder that selectively 
affects motor neurons. It leads to the degeneration of both upper and lower motor neurons, 
respectively in the motor cortex and in the brainstem and spinal cord. Different mechanisms have 
been proposed to explain the pathogenesis of the disease: protein aggregation, oxidative stress, 
impairment of mitochondrial function, transcription dysfunctions, alterations in the proteasome 
pathway, inflammation and excitotoxicity. 
A wide phenotypical variability is described, likely attributable to a combination of genetic and 
environmental factors, able to modify the clinical expression of the disease. However, the difficulty 
to focus on one specific environmental factor, the variability of such exposure in space and time and 
the interaction between environment and genetic background, hampered the evaluation of their 
possible role in ALS etiology. 
The study of geographical clusters of ALS patients has been helpful - in the past years - to get more 
insights into the pathology. Studying individuals exposed to the same environment, thus ideally 
subjected to the same exogenous stressors, could be very valuable by limiting one of the most 
confounding variables in ALS studies. Indeed, a diverse environmental exposure is almost always 
necessarily present when analyzing the large cohorts of patients that are usually required to reach 
statistically significant numbers of cases in epidemiological-type studies. 
This PhD thesis presents a multidisciplinary study performed on a small cohort of sporadic ALS 
patients, all originating from a restricted and defined geographical area. Focusing on a very limited 
geographical area, gave the chance to consider the characteristics of the surrounding environment 
and allowed to raise hypotheses on the possibly involved stressors acting on the local population, 
being those environmental or dietary contributions. 
In detail the experiments performed can be divided into five main themes: 
 To assess possible differences in the diet of ALS subjects and healthy controls and to provide 
information as for whether the consumption of one or more foods were associated to the 
disease status by an exploratory questionnaire submitted to the subjects involved in the study. 
There were no evident differences in the nutrition habits of ALS subjects with respect to healthy 
controls. 
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 To determine concentrations of a selected panel of metals in serum and whole blood with ICP-
MS. Metals analyzed have been chosen based on their biological relevance and previous works. 
Concentrations of As, Al, Mn, Se, Ni, Pb, Hg, Cu, Fe, Zn, Co, Cr, Ba, Sn, U, V, Sr have been 
evaluated in serum, while an additional analysis of Cr, Mn, Co, Cu, Zn, As, Se, Pb and Hg has 
been performed on whole blood. The most striking result comes from the association of lower 
levels of serum As with the disease status, an occurrence reported for the first time. 
 To analyze the serum proteome for the first time in ALS studies, through two-dimensional 
electrophoresis, to dissect the possible links between circulating proteins and circulating metals 
and to exploit this technique to look for a possible panel of easily accessible disease biomarkers. 
Proteins in which was registered an alteration are involved in the Acute Phase Response. 
Indeed, the different expression with respect to controls could be related to the disease status 
of the subjects. Alterations in some proteins related to lipid homeostasis have been detected, 
that is consistent with a proposed metabolic shift towards an increased peripheral use of lipids 
in ALS. Deregulation of lipid homeostasis proteins seems to be more directly linked in 
modulating the disease progression, as supported from literature data. 
 To evaluate the genetic background of patients by analyzing the most frequently mutated genes 
(SOD1, FUS, TDP43 and C9orf72) to exclude a genetic cause of the disease, giving more 
relevance to the environmental exposure as a risk factor. APOE4 and PON genotypes have been 
evaluated in the light of the results obtained from the proteomic studies. The allelic frequency 
for the APOE*4 allele, associated to neurodegeneration, is 3-fold higher as well as 
APOE*3/APOE*4 genotype in the patients’ group than in control’s. 
 To evaluate the DNA oxidative stress by Comet Assay, since it is well known that cellular 
oxidative stress is involved in the disease. Furthermore, metals impaired homeostasis may 
exacerbate oxidative stress via Fenton reactions. In literature at present there are few works 
evaluating this aspect with this approach. The levels of endogenous DNA damage did not differ 
between ALS and control group.  
To overcome the obvious limits related to the small number of subjects necessarily involved in this 
study, advantage was taken from the application of a multifactorial statistical evaluation, based on 
a machine learning software. This software, belonging to the artificial neural networks architecture, 
was specifically designed to analyze complex problems, where the number of variables significantly 
exceeds the amount of subjects involved in the study, as usually is in the case of rare diseases. 
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Great amount of data is, nowadays, a limit in understanding results of experiments performed with 
more and more sophisticated technologies, especially in complex diseases such as ALS. The 
application of new statistical analyses, based on machine learning, where data are the basis of the 
creation of models to interpret interactions among variables, would be the key to translate raw data 
into understandable models. 
The lack of an effective pharmacological treatment in ALS leads to rapidly looking for alternative 
approaches to modulate this devastating disease. To this purpose, a nutritional intervention, with 
the development of specific nutritional formulas, would be an effective tool to intervene on the 
patients’ lipid profile and to contrast potential metal’s homeostasis impairment. Thus, development 
of such formulations is strongly supported from the evidences raised from this study, together with 
its application in clinical trials. 
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INTRODUCTION 
Amyotrophic Lateral Sclerosis 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder with unknown etiology and 
adult onset. It is characterized by the progressive degeneration of motor neurons in the motor 
central cortex, in the brain stem, and in the anterior horn of spinal cord. Motor neuronal death leads 
to muscle weakness, gradual loss of muscle functionality and total paralysis, leading to death, 
generally in 3 to 5 years from symptoms onset, due to respiratory failure. 
The most characteristic clinical feature is motor weakness starting locally. In two-thirds of the 
cases first symptoms are cramps and limb weakness, the remaining third presents bulbar problems, 
like dysarthria and dysphagia, a condition that usually leads to death more rapidly. In rarer cases, 
first symptoms could be represented by respiratory failure, cognitive impairment or behavioral 
disturbances (Ajroud-Driss and Siddique 2014). 
The term Lateral Sclerosis, refers to the autoptic characteristics of the spinal cord, whose 
lateral columns result hard to palpation. This is consequent to the occurring reactive astrogliosis, 
that leads to the alteration of the corticospinal tracts where the axons of damaged motor neurons 
are localized. The term Amyotrophic refers instead to the neurogenic muscle atrophy. The loss of 
innervation leads to muscular weakness, and degeneration of fibers up to paralysis of limbs and 
muscles involved in deglutition and speech (Wijesekera and Leigh 2009). 
ALS has an overall estimated annual incidence of 1.5-2.7/100,000 and a prevalence of 3-
5/100,000 (Al-Chalabi and Hardiman 2013). The mean age at onset is 55-65 years, only a few 
percentage of cases presents an early onset, before 30 years of age (Wijesekera and Leigh 2009). 
The mean duration of disease is about 32 months, but it can vary from 23 to 48 months. However, 
20% of patients can survive up to 5 years and a lower amount (10%) is still alive after 10 years from 
onset (Harms and Baloh 2013). 
No evident family history is present in most of the cases (90%, defined as sporadic ALS or SALS), 
while only the remaining 5-10% have a family history with a Mendelian inheritance (familial ALS or 
FALS) (Li and Wu 2016). A rarer third form of the disease, called juvenile ALS or jALS, has an onset 
usually before 25 years of age (Dion et al. 2009); it is distinct from the other forms of ALS since it 
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generally is familial and with a relatively benign course of disease. The other different forms of the 
disease (SALS and FALS) are clinically undistinguishable, even if generally the spectrum of symptoms 
in ALS is very broad. The only difference resides in the age at onset, usually earlier in familial forms 
(46 years of age), whereas sporadic forms have a mean age at onset at 56 years (Kiernan et al. 2011). 
In the familial form of the disease usually the survival is about 5 years longer than in sporadic 
patients (Wijesekera and Leigh 2009). 
 Despite great efforts in research, the etiology of the disease is still unknown and an effective 
treatment is still not available. More than 100 drugs have been tested up to now, some of them 
even in Phase II and III of human clinical trials, but resulted inefficient and inapplicable in the clinical 
practice. At date the only drug approved by FDA is Riluzole, that showed only modest effect by 
prolonging lifespan of patients of few months (Miller et al. 2007). 
 
Clinical features 
ALS is a progressive neurodegenerative disease affecting selectively motor neurons. It represents 
the most common form of the so-called Motor Neuron Diseases (MNDs). This definition groups 
different progressive diseases that have as a common feature, namely, the final loss of the first 
and/or the second motor neurons (Mancuso and Navarro 2015). The most characteristic symptom 
is the slowly progressive, painless, muscular weakness in one or different regions of the body, 
without changes in the ability to feel. Together with weakness, also spasticity, fasciculation, and 
cramps may be present (Wijesekera and Leigh 2009). 
Diagnosis of ALS requires presence of both upper and lower motor neurons defects and 
progression of disease. When Lower Motor Neurons (LMN) are involved, involuntary muscle 
twitching (fasciculation) may occur; other typical signs of LMN impairment are cramps, muscular 
hypotonia, and atrophy. Subjects with Upper Motor Neurons (UMN) involvement present generally 
stiffness and hyperreflexia. Other UMN symptoms are spasms and sudden straightening movements 
of lower limbs (spasticity). Babinski’s (anomaly of the cutaneous plantar reflex) and Hoffman’s (same 
for the upper limbs) signs are variably present in the early stages of disease. These signs are the 
result of the degeneration of upper and lower motor neurons in brain and spinal cord. Small 
interneuron loss in the motor cortex and in the spinal cord may also occur, affecting muscles that 
control eyes movement and urinary sphincters (Pasinelli and Brown 2006). 
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The disease may present bulbar and spinal onset forms (Figure 1). About 75-80% of patients 
have the spinal onset form. Symptoms are related to focal muscle weakness, starting either distally 
or proximally, more frequently in upper than in lower limbs. Patients with upper limbs onset may 
present reduced finger dexterity, cramping, stiffness and weakness of hand muscles. Those with 
lower limbs onset may suffer from stumbling, tripping or difficulty in running. Focal muscle atrophy 
involves the muscles of hands, forearms or shoulders in the upper limbs, and proximal thigh or distal 
foot muscles in the lower limbs. The Hoffmann’s and Babinski’s signs may be positive (Wijesekera 
and Leigh 2009). Usually the disease onset is asymmetrical, but limbs weakness and wasting 
inevitably spreads. Most patients with time develop respiratory symptoms. 
Fig.1. Motor neurons selectively affected in ALS patients 
 
Occasionally encountered symptoms include bladder dysfunction, sensory symptoms, cognitive 
symptoms and multi‑system involvement (e.g. dementia, Parkinsonism). 
The remaining 20-25% of cases present bulbar onset form. Common features of these subjects 
include dysarthria or dysphagia for solids or liquids, up to complete loss of verbal communication 
and fasciculation in the tongue. Limbs symptoms may occur simultaneously or within 1-2 years. 
Almost all patients present sialorrhea due to difficulty in swallowing and bilateral facial weakness in 
the lower part of the face. The fatal event is commonly denervation of respiratory muscles, 
occurring within 5 years from disease onset (Valdmanis and Rouleau 2008).  
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In ALS patients cognitive abnormalities are present, ranging from executive dysfunctions to 
Fronto-Temporal Dementia (FTD), present in 5-15% of patients (van Langenhove et al. 2012). FTD 
indicates a heterogeneous group of neurodegenerative dementias, different from Alzheimer’s 
Disease, characterized by progressive deterioration of the frontal and temporal lobes in the brain 
(Sieben et al. 2012). Progressive FTD signs are: personality abnormalities, lack of interest in personal 
care, obsessive and stereotyped attitudes, reduction of empathy, disinhibition, delusions and 
hypersexuality (Phukan et al. 2007). 
In a large group of subjects with FTD, inclusion of TDP-43 in cortical neurons have been 
described, similar to those found in ALS patients’ motor neurons (Neumann et al. 2006). These 
cases, presenting clinical features of both the pathologies are referred to as ALS/FTD. Furthermore, 
several molecular biology studies have found that ALS and FTD may be caused by mutations in the 
same genes: C9ORF72 (Chromosome 9 open reading frame 72), TARDBP (TAR DNA-binding protein), 
FUS (FUsed in Sarcoma/Translated in LipoSarcoma), GRN (Progranulin), VCP (Valosin Containing 
Protein), MATR3 (Matrin 3), CHCHD10 (Coiled-coil-Helix-Coiled-coil-Helix Domain containing 10), 
TUBA4A (Tubulin Alpha 4A) e TBK1 (TANK-binding kinase 1) (Sabatelli et al. 2016). Nowadays is 
accepted that there are common pathological processes in ALS and FTD, and that the two diseases 
are part of a continuous spectrum of disease with overlapping symptoms (Figure 2). 
 
Epidemiology 
Usually ALS is classified in 3 categories: Sporadic ALS, Familial ALS and Western Pacific ALS. 
Sporadic ALS (SALS)  
SALS represents the most common form of the disease and it is diagnosed when the loss of the first 
and/or the second motor neuron occurs in only one member of a family (Mitchell and Borasio 2007). 
Etiology is still unknown and disease is supposed to be caused following a complex interaction of 
genetic and environmental factors; however, genetic influence is far from being completely 
understood, since only 10% of sporadic cases presents a pathological mutation in the known 
responsible genes (Renton et al. 2014). Incidence in North America and Europe is similar, at about 
1.5-2.5/100,000 person/year (Chiò et al. 2013). Incidence in Italy is 2.64/100,000 inhabitants per 
year with very small differences in data collected from different groups in different regions (Scialò 
et al. 2016). 
11 
 
 
Fig. 2. ALS and FTD causative genes. Size of circles reflects frequency of mutation (Eisen and Krieger 2013) 
 
An increment of 46% of incidence and 57 % of mortality rates has been described in the last 
years of the past century, with respect to the previous decades (Worms 2001), particularly in 
Mediterranean countries, in the female population, and in people with more than 75 years of age. 
This likely could be dependent from an increase in life expectancy of population in the last decades 
and from a better understanding of the disease, leading to a better case ascertainment. Recent 
studies showed that in the last ten years prevalence of the disease did not increase (Zarei et al. 
2015). The prevalence of ALS is estimated at 4‑6/100,000 persons with a uniform distribution across 
the world. 
Mean age at onset is 55-65 years of age, with 80% of subjects presenting the first symptoms 
in the ages between 40 and 80 (Chiò et al. 2009). Incidence shows a great variability in different age 
groups, reaching its peak in ages 60-79 and rapidly decreasing after 80 years of age (Logroscino et 
al. 2005). This is likely related to the fact that elder patients may present symptoms easily mistaken 
as signs of aging or that may be masked by other diseases. Conversely, an age-specific peak in 
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incidence curve suggests that a time dependent exposure to environmental risk factors could be 
involved in the disease. Early onset might represent a consequence of harsher exposure to these 
risk factors (Sabatelli et al. 2013). 
Survival is commonly of 3-5 years from symptoms’ onset. It can be prolonged by ventilation 
support that can ease breathing problems. Although it does not affect progression of the disease, it 
can improve or at least maintain quality of life in people with non-severely compromised bulbar 
function (Radunovic et al. 2010). However, about 10% of patients has a survival longer than 10 years. 
Familial ALS (FALS) 
ALS is defined familial in case of the presence of at least two affected relatives in less than four 
generations; in 50-75% of cases only two affected subjects are reported within the same family 
(Sabatelli et al. 2013). This form of the disease presents a wide phenotypical and genetic 
heterogeneity, even in the presence of the same mutation within the same family. 
The autosomal dominant inheritance pattern is the most common when the onset is in adult 
age; recessive transmission is more frequent in juvenile onset (Ajroud-Driss and Siddique 2014). A 
dominant X-linked inheritance pattern is described only in one family (Wilkins et al. 1977). Between 
1958 and 1996 several epidemiological studies have been performed, indicating about 0.8-13.5% of 
patients with familial ALS. However, the frequency of FALS indicated in these studies is very variable, 
due to several reasons: 
- non-homogeneous diagnostic criteria, 
- incomplete genealogical investigations, 
- inadequate recognition of different subtypes of ALS in different family members, 
- reluctance of patients to report a hereditary disease, 
- loss of contact between family members, 
- early death in family members due to causes different from ALS, 
- earlier age at onset in patients of the successive generations (anticipation), 
- incomplete disease penetrance, 
- misdiagnosis of ALS in some family members, 
- illegitimacy. 
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Nowadays it is established that cases of authentic FALS account for the 5-10% of total cases 
(Ajroud-Driss and Siddique 2014). Symptomatology of familial ALS is overlapping to that of the 
sporadic form of the disease, except for little differences (Li et al. 1988): 
- earlier age at onset (about 10 years before), 
- Gaussian distribution of age at onset with respect to an age-dependent incidence in SALS, 
- both genders are affected in the same proportion, 
- generally longer disease duration, 
- lower limbs onset is more frequent, 
- degeneration of the posterior columns of the spinal cord, spino‑cerebellar traits, and dorsal 
nucleus of Clarke is evident in 70% of patients with familial ALS. 
Mean age at onset is 45.7 ± 11.3 years with a median survival of 24 months. Usually, pathology 
is focal and asymmetric at onset, then tends to spread in a contiguous way. As in the sporadic form, 
phenotypic heterogeneity is present: age at onset may vary up to 30 years, duration of illness and 
signs at onset may vary as much (Ajroud-Driss and Siddique 2014). 
Western Pacific ALS 
In the Western Pacific area, the prevalence of ALS is 50-100 times higher than in the rest of the 
world. Four well studied geographical clusters are known: the Guam island in Micronesia, the 
Japanese Kii peninsula, the Western coast of former West Papua New Guinea and an isolated tribe 
at Anguru on Groote Eylandt in the Gulf of Carpentaria (North Australia). In the 1960s, in Guam, 
incidence of ALS was about 179/100,000 for men and 60/100,000 for women. Scientists refer to this 
form of disease as Amyotrophic Lateral Sclerosis/Parkinsonism‑Dementia Complex (ALS‑PDC) 
because subjects are prone to manifest atypical Parkinsonism, dementia, motor neuron disease, or 
a combination of these three phenotypes. The cause of the disease is still unknown, but some 
evidences point towards a complex interaction of genetic susceptibility and a strong environmental 
influence. Indeed, despite a positive family history for 45% of patients, it was not possible to identify 
a mendelian inheritance pattern. The annual incidence declined since 1955, indicating that causes 
may have ended decades ago (Kurland 1988; Plato et al. 2003). 
Two environmental hypothesis - related to nutritional habits - have been proposed. High levels 
of aluminum and manganese and low levels of calcium and magnesium were found in drinking water 
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and soil samples in Guam, the Kii Peninsula and Western New Guinea. Deposition of aluminum in 
affected neurons was described (Perl et al. 1982); deficiency of calcium and magnesium has been 
hypothesized to increase aluminum uptake as alternative source of cations, thus possibly leading to 
neuronal damage and death (Garruto et al. 1989). Alternatively, higher iron levels, following 
aluminum accumulation, may cause oxidative stress in vulnerable neurons. 
Another hypothesis relates to the possible presence of a neurotoxin in the affected area. 
Neurological symptoms in monkeys fed with large doses of beta‑methyl‑amino‑L‑alanine (BMAA), 
an unusual, neurotoxic, excitatory amino acid were described in the late 1980s (Spencer et al. 1987). 
This toxin is present in low quantities in Cycas circinalis seeds and it is easily removed after washing, 
thus doses to achieve neurotoxicity were unrealistic to achieve. However, Cox and Sacks raised the 
theory of bio magnification of this toxin exerted by flying foxes (Pteopus ariannusmariannus). This 
species of megabats consume large amounts of Cycads leaves and seeds and Chamorro indigenous 
of Guam, in turn, traditionally feasted on these animals (Cox and Sacks 2002). In the last 30 years 
ALS gradually disappeared from Guam, in coincidence with huge and rapid ecological and socio-
economic changes, following deforestation for the construction of huge military bases and 
westernization of lifestyle, that changed food collection and dietary habits, possibly removing the 
ALS-PDC exogenous factors (Chen 1995). 
 
Etiology 
Despite intense efforts in research, pathogenesis of ALS is still unknown and it is not clear if it is the 
same across single individuals. It is believed that to trigger the disease, the interplay of multiple 
genetic and environmental factors is required (Oskarsson et al. 2015). 
Genetics 
ALS is considered a complex genetic disease in which multiple cellular mechanisms, not mutually 
exclusive, can be affected (Shaw 2005). The number of genes involved in the disease increased in 
the last years, along with the hope of identifying common pathways related to the disease. Most 
frequently mutated genes code for proteins involved in antioxidant response, axonal transport, 
angiogenesis and RNA processing (Al-Chalabi and Hardiman 2013). 
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Nineteen genes located in twenty-one chromosomal regions have been associated with ALS, 
jALS and ALS/FTD (Li and Wu 2016) (Table 1). Genetic architecture of ALS is complex: mutations in 
SOD1, FUS and TARDBP genes are considered at high risk of causing the disease; mutations in other 
genes are less frequent (Leblond et al. 2014). An expansion of six nucleotides in C9ORF72  gene, 
nowadays, is the most frequent genetic alteration associated with ALS (DeJesus-Hernandez et al. 
2011; Renton et al. 2011).  The improvement of genetic analyses has made a large number of genes 
considered as "candidate genes”; however, they present a low contribute in ALS, and association 
studies are still required (Leblond et al. 2014). The so called modifier genes are able to alter ALS 
expression and the phenotype (age at onset, disease course, prognosis) given by the mutated 
causative gene; among these there are SMN (Survival Motor Neuron), CNFT (Ciliary Neurotrophic 
Factor), KIFAP3 (Kinesin associated Protein 3), UNC13A (Unc-13 homolog A), ZNF512B (Zinc Finger 
Protein 512B), APOE (Apolipoprotein E), PON (Paraoxonase), HFE (Hemochromatosis) MAOB 
(Monoamine Oxidase B), EPHA4 (EPH receptor A4), VEGF (Vascular Endothelial Growth Factor) 
(Marangi and Traynor 2015). 
SOD1 was the first gene associated to ALS in 1993 (Rosen et al. 1993). It is ubiquitously 
expressed and its nucleotide sequence is highly conserved (Wang et al. 2006). SOD1 gene codes for 
the Cu-Zn Superoxide Dismutase enzyme, a protein localized in cytosol, nucleus, peroxisomes and 
mitochondria; it is widely expressed in mammalian central nervous system (Pardo et al. 1995). It 
functions as a homodimer protein, where each subunit is composed of 153 amino acids and binds 
its own copper and zinc ions in the active site. Its function is to catalyse the conversion of the 
Superoxide radical (O2¨) into molecular oxygen (O2) and hydrogen peroxide (H2O2), that in turn are 
removed by the glutathione peroxidase and catalase enzymes (Bunton-Stasyshyn et al. 2014) (Figure 
3). Mutations generally affect either amino acids in the active site, involved in the binding of cations, 
or alter the protein folding and stability (Andersen et al. 1997). 
 
Fig. 3. Function of SOD1 enzyme.  
 
 
Type Gene Chr Protein Function Heredity FALS SALS FTD 
ALS1 SOD1 21q22.1 Cu-Zn Superoxide Dismutase Antioxidant enzyme AD, AR, de novo Y Y Rare 
ALS2 ALS2 2q33.2 Alsin CT, ESC AR Y +jALS N N 
ALS3 UN 18q21 UNK UNK AD (one family) Y N UNK 
ALS4 SETX 9q34 Senataxin RNA processing AD Y +jALS Y N 
ALS5 SPG11 15q21.1 Spatacsin 11 UNK AR Y +jALS N Rare 
ALS6 FUS 16p11.2 Fused in sarcoma/translated in 
liposarcoma 
RBP AD, AR, de novo Y +jALS Y Y 
ALS7 UNK 20p13 UNK UNK AD (one family) Y N UNK 
ALS8 VAPB 20q13.3 Vescicle-associated membrane 
protein-associated B and C 
CT, ERGP AD Y N N 
ALS9 ANG 14q11.2 Angiogenin RBP, Angiogenesis AD Y Y Y 
ALS10 TARDBP 1p36.22 TAR DNA-binding protein 43 RBP AD Y Y Y 
ALS11 FIG4 6q21 FIG4 phosphoinositide 5-
phosphatase 
PRD, ERGP, CT AD Y Y N 
ALS12 OPTN 10p13 Optineurin PRD, ERGP, CT AD, AR Y Y Y 
ALS13 ATXN2 12q24 Ataxin 2 Triplet Expansion AD N Y N 
ALS14 VCP 9p13 Valosin containing protein PRD AD Y N Y 
ALS15 UBQLN2 Xp11.21 Ubiquilin 2 PRD XR Y +jALS Y Y 
ALS16 SIGMAR1 9p13.3 Sigma receptor 1 ERGP AD Y +jALS N Rare 
ALS17 CHMP2B 3p12.1 UNK PRD, CT, ESC AD Y Y Y 
ALS18 PFN1 17p13.2 Profilin 1 Actin polymerization AD Y Y Y 
ALS19 ERBB4 2q33.3-q34 Erb-b2 receptor tyrosine kinase CT AD Y N N 
ALS20 hnRNPA1 12q13.1 UNK RBP AD Y Y Y 
ALS21 MATR3 5q31.3 Matrin 3 RBP AD Y Y Y 
ALS/FTD2 C9ORF72 9p21.2 UNK CT, hexanucleotide 
expansion 
AD Y Y Y 
ALS/FTD GRN 17q21.31 Progranulin Cellular growth 
regulation 
AD N Y Y 
Table 1: UNK: unknown; CT: cellular trafficking; ESC: endosomal sorting complex; ERGP: endoplasmic reticulum-golgi pathway; RBP: RNA Binding Protein; PRD: 
protein degradation; AD: Autosomal Dominant; AR: Autosomal Recessive; XR: Chromosome X-linked.
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Mutations in the SOD1 gene account for the 20% of FALS cases and 1-2% of SALS cases (Li and 
Wu 2016). The genotype-phenotype correlation is not clear, as there is a great variability both in 
disease onset and course, clinical features, age and site at onset; survival may vary within the same 
family (Penco et al. 2011). Animal model studies indicate a possible pathologic gain of function of 
mutated SOD1, leading to a lowering of antioxidant function of the enzyme and a higher tendency 
to aggregation and mislocalization (Kaur et al. 2016). 
FUS gene mutations in ALS have been described in 2009 (Kwiatkowski et al. 2009; Vance et al. 
2009). FUS is a gene ubiquitously expressed, coding for a 526-residues protein "fused in sarcoma / 
translated in liposarcoma. The protein has a nuclear localization, it is able to bind DNA and RNA and 
it is involved in RNA splicing, transport, and maturation (Lagier-Tourenne et al. 2010). The protein 
is composed of several different domains and the most frequently mutated residues lie within the 
C-terminal nuclear localization signal (Andersen and Al-Chalabi 2011). 
FUS is found mutated in 3-5% of FALS cases and in 1% of SALS cases (Chen et al. 2013). Subjects 
harbouring a FUS mutation usually present an earlier age at onset and a more rapid progression of 
disease; bulbar onset is more frequent (Li and Wu 2016). 
The TARDBP gene codes for a ubiquitously expressed protein of 43 kDa called TDP-43. The 
protein is found ubiquitinylated in high amounts in neuronal cytoplasmic inclusions in subjects with 
ALS and/or FTD (Neumann et al. 2006). Similarly to FUS, TDP-43 exerts its physiological function in 
nucleus, where it is involved in RNA transcription, splicing, transport, and maturation (Lagier-
Tourenne et al. 2010). Mutations in the TARDBP gene account for the 4% of FALS cases and 1% of 
SALS cases (Li and Wu 2016). Most of the mutations are located in a region essential for protein 
solubility and cellular localization (Pesiridis et al. 2009). TDP-43 mutations are found also in patients 
with FTD and Parkinson Disease (Li and Wu 2016). In 2011 two independent groups identified the 
C9ORF72 gene as associated with ALS and FTD (DeJesus-Hernandez et al. 2011; Renton et al. 2011). 
Differently from other ALS genes, where exonic mutations are usually missense and nonsense, the 
pathological genetic event in C9ORF72 is a hexanucleotide expansion (G4C2) in a non-coding region 
(Figure 4). 
The region where this alteration is localized is highly conserved through different species 
(Leblond et al. 2014) and, depending on the protein isoform, it can lead to missed transcription of 
the gene (loss-of-function) or to the transcription of the repeat itself, leading to a toxic gain-of-
function through the accumulation of transcripts in nuclear RNA foci (Woollacott and Mead 2014). 
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Fig. 4. C9ORF72 gene structure. V1, V2, V3 represent the three alternative transcripts. Grey boxes represent 
non coding exons, white boxes represent coding exons. Localization of the hexanucleotide expansion is 
indicated (DeJesus-Hernandez et al. 2011). 
 
At present little is known about the function of the coded protein; bioinformatic analyses 
predicted a possible role in endosomal trafficking and autophagy (Levine et al. 2013). The amount 
of expansions is highly variable but in healthy subjects it usually does not exceed 25 repeats, 
whereas in affected subjects there are more the 30 (and up to hundreds/thousands) repeats (Rohrer 
et al. 2015). C9ORF72 expansion is the most frequent cause of ALS and FTD: it has been identified in 
40% of FALS cases, 7% of SALS cases, 25% of familial cases of FTD and 6% of sporadic FTD. ALS 
patients bearing a C9ORF72 expansion show a great phenotypic heterogeneity. Subjects present 
bulbar onset and cognitive impairment more frequently, have a rapid progression and a lower 
survival (Li and Wu 2016). 
Despite most of the mutations show a typical mendelian Autosomal Dominant pattern of 
inheritance, a monogenic model of heredity does not fully explain the genetics of ALS (Singleton et 
al. 2010). Indeed, interactions between different multiple genetic variants may contribute to ALS 
susceptibility. This could also explain the huge phenotypical differences between subjects bearing 
the same causative mutation and the incomplete penetrance of mutations found within the same 
family (Marangi and Traynor 2015). Different studies support this model of oligogenic disease by 
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describing patients with simultaneous mutations in two different causative genes (Chio et al. 2012; 
Van Blitterswijk et al. 2012). 
Oxidative Stress 
Oxidative stress is the result of an imbalance between production of Reactive Oxygen Species (ROS) 
and the cell ability of scavenging them through a variety of mechanisms. ROS are - in most cases - 
the result of the leakage of electrons from the mitochondrial respiratory chain, leading to the 
production of superoxide anion (O2¨) and hydrogen peroxide (H2O2). Neither superoxide nor 
hydrogen peroxide is highly reactive, but each undergoes further reaction to produce more potent 
oxidants (Barber and Shaw 2010).  
The hypothesis of an involvement of oxidative stress in ALS is supported by the fact that SOD1, 
one of the most important antioxidant enzymes, is mutated in almost 20% of familial cases. This 
protein is a key regulator of intracellular red-ox equilibrium and its alteration may trigger a cyclic 
process in which ROS can lead to cellular damage and thus neurodegeneration (Ferrante et al. 1997). 
Post-mortem tissues from ALS patients reveal a broad oxidative damage to lipids, proteins and DNA 
(D’Amico et al. 2013). Oxidative stress may be caused by several endogenous and exogenous 
influences. The main endogenous sources of ROS are mitochondria, so intense efforts have been 
done in studying mitochondria related pathogenic mechanisms (Cozzolino et al. 2015). Oxidative 
stress may also be linked to the other proposed pathogenic pathways, in ways not fully clear yet, by 
causing RNA dysmetabolism, which in turn can promote oxidative stress itself  and affects protein 
folding, creating a complex network of deleterious interactions (Bozzo et al. 2016) (Figure 5). 
Mitochondrial dysfunctions 
Mitochondria are the cell’s energy production sites through oxidative phosphorylation. They are the 
deposit of intracellular calcium and are involved in apoptosis. Several studies have demonstrated 
altered morphology in mitochondria located in proximity to the end of axons in motor and sensory 
neurons, in muscles, and in other tissues (Siklós et al. 1996). Impaired activity of Complex IV and a 
higher mutation rates in mitochondrial DNA have been reported in spinal motor neurons (Shaw 
2005). Mitochondrial dysfunctions also relate to impaired clearance of damaged organelles, defects 
in transport or morphology, induction of mitochondrial mediated apoptosis, and calcium storage 
defects (Cozzolino and Carrì 2012). 
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Fig. 5. Schematic representation of the pathogenic vicious cycle underling motor neuron degeneration in 
ALS. Oxidative stress and mitochondrial impairment are linked to protein unfolding and aggregation and to 
altered RNA metabolism (Bozzo et al. 2016). 
 
Disruption of mitochondria may be triggered by aggregation of products of mutated ALS genes 
as well as by RNA dysmetabolism and oxidative damage. In transgenic mice, mutant SOD1 localizes 
in spinal cord mitochondria before symptom onset, and this has been associated with decreased 
respiratory activity  and increased oxidative damage (Higgins et al. 2002; Mattiazzi et al. 2002). 
Physical interaction between mitochondria and the endoplasmic reticulum, usually occurring at 
specific sites called Mitochondrial Associated Membranes (MAMs), is crucial for the correct 
functioning of both compartments in calcium signalling, in lipid metabolism and mitochondrial 
bioenergetics, as well as for morphology, transport and clearance. Disturbances of these 
interactions in ALS and other neurodegenerative diseases have been documented (Manfredi and 
Kawamata 2015; Carrì et al. 2016). 
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Protein aggregation 
Correct protein folding and a preserved native three-dimensional structure are crucial to ensure 
biological function. Under certain circumstances, enhanced by mutations and environmental 
conditions, proteins tend to misfold. Protein misfolding could lead to the formation of insoluble, 
toxic protein aggregates, a hallmark of several different neurodegenerative diseases. These 
inclusions have been detected in several neural compartments in ALS animal models and in post-
mortem patient’s tissues as well (Al-Chalabi et al. 2012). In the familial form of the disease, these 
protein aggregates are mainly composed by those encoded by the mutated genes (one of the most 
present is ubiquitinylated TDP-43). When a pathological C9ORF72 repeat expansion is present, 
repeated-associate non-conventional (RAN) translation occurs (Zu et al. 2013), resulting in the 
production of dipeptide repeat proteins (DPR). DPR are considered as mediators of toxicity, since 
they can aggregate and cause endothelial reticulum (ER) stress (Ash et al. 2013; Wen et al. 2014). In 
addition, wild-type forms of TDP-43, SOD1 and FUS misfolded proteins have also been detected in 
inclusions of SALS patients (Neumann et al. 2006; Blokhuis et al. 2013). 
With so many evidences towards protein misfolding to be crucial in ALS, proteostasis 
impairment is likely to be a central feature in the disease. Indeed, several disease-causing genes 
code for protein whose function is linked to proteostasis (Parakh and Atkin 2016) and particularly in 
ubiquitin-proteasome system (UPS), in chaperone mediated autophagy (CMA), and in 
macroautophagy (Ciechanover and Kwon 2015). Unfolded protein response (UPR) is a cellular 
mechanism able to reduce the load of misfolded proteins, and in the last years its role in ALS 
pathogenesis has been widely discussed (Kanekura et al. 2009) since markers of ER stress and UPR 
have been found in elevated levels in spinal cords of SALS patients (Atkin et al. 2008).  
Axonal transport dysfunction 
Intracellular inclusions containing neurofilaments have been found in degenerated motor neurons 
(Shaw 2005). Neurofilaments represent the major component of neuronal and motor neuronal 
cytoskeleton, responsible for maintaining cell shape and axon calibre. They are formed upon 
aggregation of subunits, assembled in cellular soma and transported in the axon with a slow 
movement characterized by progressive phosphorylation and anterograde/retrograde transport 
systems. They play a crucial role in maintaining neuronal structure and axonal transport, so a 
malfunctioning of these finely tuned processes could lead to motor neuronal degeneration (Perrot 
et al. 2008). Mutations in the DCTN1 gene - coding for the protein dynactin, part of dynein-dynactin 
molecular motor - are a rare cause of ALS. Problems in microtubule binding and defects in vesicular 
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trafficking resulting in ER morphology abnormalities and autophagy activation have been observed 
(Münch et al. 2005; Laird et al. 2008). Rare mutations have also been detected in NFH protein in a 
site where a crucial phosphorylation occurs, resulting in toxicity due to neurofilament 
disorganization (Brettschneider et al. 2006). Also profilin 1, an actin binding protein intervening in 
actin polymerization, has been found mutated in ALS patients (Wu et al. 2012). 
Excitotoxicity 
The only approved pharmacological treatment for ALS consists in Riluzole, an inhibitor of glutamate 
release. High levels of glutamate have been found both in plasma and in CSF of ALS patients. Defects 
in glutamate transporters localized in glial cells, whose function is to rapidly inactivate glutamate 
action after release, have been described both in animal models and in human patients and could 
possibly lead to higher levels of this excitatory neurotransmitter in the extracellular compartment. 
All these evidences led to hypothesize that abnormal levels of L-glutamate could trigger a signalling 
cascade leading to motor neuronal death (Struzyńska 2009). In detail the hyper-activation of 
glutamate receptors could lead to an uncontrolled calcium influx in cells, that could trigger nucleic 
acid damage, lipid peroxidation and mitochondrial disruption, leading in the end to cellular death. 
RNA processing 
Several ALS associated genes have a role in RNA processing (FUS, TARDBP, SETX, hnRNPA1, MATR3, 
ANG). This complex pathway includes transcription, intron removal through splicing, RNA 
maturation, editing, transport and degradation. Proteins coded by these genes are physiologically 
located into the nucleus, with only a small fraction in the cytoplasm. Mutated proteins, instead, are 
mostly found in cytoplasm, with only minor presence in the nucleus. In spite of the still unclear role 
of the protein encoded by C9ORF72 gene, it has been demonstrated that the hexanucleotide 
expansion associated to the disease could promote the formation of RNA foci into the cytoplasm - 
where RNA binding proteins are sequestered - lowering the amount of available functional proteins 
(Barber and Shaw 2010). It remains to be clarified if the pathological event in these processes is in 
a cytotoxic gain of function or a depletion from the nucleus of those proteins involved in RNA 
processing (Peters et al. 2015). 
Inflammation 
Microglial and dendritic cells are involved in early processes of motor neuron degeneration, as their 
activation leads to inflammatory status in the neural compartment (Glass et al. 2010). Studies in 
mice expressing mutated SOD1 protein showed that the expression of the mutated protein is not 
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sufficient to promote motor neuronal degeneration by itself, but the involvement of other non-
neuronal cells is required. Conversely, wild-type motor neurons surrounded by SOD1 mutated cells 
may present signs of the pathology (Clement et al. 2003). ROS released from damaged motor 
neurons can activate glial cells. Activated microglia becomes toxic resulting in release of further ROS, 
of reactive nitrogen species, and of pro-inflammatory cytokines that activate, in a self-sustaining 
loop, neighbouring glial cells. Mediators released by motor neurons enhance the switch from 
neuroprotective and anti-inflammatory microglia to the release of neurotoxic and pro-inflammatory 
cytokines such as IL1β, TNFα, and IL-6 (Shaw 2005). 
 
Potential Environmental Factors 
Nowadays, environmental contribution to the etiology of ALS remains elusive. There is no specific 
environmental factor proven to cause ALS, but a lot of hypotheses have been raised in the last years, 
since genetics explains only a small percentage of the cases. Even among clear-cut genetic cases, 
variability is extremely high and may be influenced by different environmental exposures. In ALS, it 
is highly probable that both known and unknown susceptibility genes interact with environmental 
factors to modulate disease risk. Challenges in assessing influence of environmental factors are hard 
to overcome. The variables to consider, in evaluating the exposure, are potentially infinite both in 
space and time. Specific exposures can be evaluated only in the presence of a prior hypothesis (Al-
Chalabi and Hardiman 2013). However, several factors have been discussed to be involved in ALS 
etiology, but most of them in a controversial way. 
Gender 
Male gender is one of the strongest risk factors for SALS. In fact, males have 1.5 time increased risk 
to develop ALS, with respect to females (Mehta 2015). Genetics, as seen, may play an important 
role, but up to now only a very rare mutation in the Ubiquilin 2 gene lies in the X-chromosome. 
Hormone influences may account for the differences in ALS risk between gender. The sex hormone 
testosterone has been suggested as a risk factor for ALS, and higher prenatal circulating levels of 
testosterone possibly influence motor-neuron vulnerability in later life (Vivekananda et al. 2011). 
Hormone influence is supported also by the fact that incidence of ALS becomes equivalent between 
the genders after menopause. Pregnancy has been described - in few studies - to have a possible 
role in unmasking latent ALS, probably due to a decrement of estrogens levels especially in patients 
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lacking the ability to inactivate efficiently superoxide radicals as a result of mutations in the SOD1 
gene (Chiò et al. 2003; Lunetta et al. 2014). Indeed, estrogens are known to have a potential 
neuroprotective eﬀect in Parkinson’s and Alzheimer’s diseases (Tang et al. 1996; Benedetti et al. 
2001). Beyond the biological differences, males and females also differ in activities leading to 
different environmental exposures (Oskarsson et al. 2015).  
Geographic clusters 
Modern epidemiology is more and more focusing in investigating geographical clusters in order to 
dissect complex diseases. However, such a methodology is difficult to apply in a disorder as ALS 
since usually latency between disease onset and time of exposure is unknown or hard to assess. 
Most of the studies conducted on geographical clusters are aimed at epidemiologically identifying 
them, rather than at evaluating potential causes of this phenomenon. Indeed, the most used 
approach relies on performing long and detailed prospective, longitudinal observations over a 
lifetime in large numbers of people (Al-Chalabi and Hardiman 2013).  
This approach led to increase knowledge of the disease in the case of ALS-PDC syndrome in 
the island of Guam, as described above. In two studies performed on Spanish population, ALS 
frequency - adjusted for age, sex, and mortality rate - showed a North-South gradient (Veiga-Cabo 
et al. 1997; Alonso et al. 2011). Clusters based on residence at diagnosis or death have been 
identified in different ALS population from studies based on mortality data from Italy (Uccelli et al. 
2007; Ragonese et al. 2012; Nicoletti et al. 2016), UK (Keren et al. 2014), Finland (Sabel et al. 2009), 
New Jersey (USA) (Henry et al. 2015) and France (Boumédiène et al. 2011). However a considerable 
fewer number of studies have aimed at evaluating the possible environmental causes of the origin 
of these clusters (Vinceti et al. 2012; Kihira et al. 2013; De Benedetti et al. 2016). At last, 
geographical clusters might be suspected in a case of a local genetic founder effect, as it has been 
hypothesized in the case of Kii Peninsula in Japan, where the higher prevalence of ALS has been 
partially explained by the presence of C9ORF72 hexanucleotide repeat expansion (Ishiura et al. 
2012). 
Smoking 
Several studies have included tobacco smoking among the potential risk factors for ALS (Kamel et 
al. 1999; Armon 2009; De Jong et al. 2010). However, findings are not conclusive, since seven studies 
showed an increase ALS risk in smokers, whereas 14 showed no increased risk. If a risk exists, it 
seems to be confined to female smokers, particularly in post-menopausal women (Al-Chalabi and 
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Hardiman 2013). It is not clear if the hypothesized risk could be associated to increased oxidative 
stress or to nicotine and other toxic substances contained in tobacco smoke. 
Diet and BMI 
An inverse association between dietary antioxidant intake and lower risk for ALS has been widely 
investigated. Among antioxidants, Vitamin E was one of the most studied, both in terms of regular 
use and duration of supplementation, in different cohorts of subjects (Ascherio et al. 2005; Veldink 
et al. 2007; Okamoto et al. 2009). A more recent, huge study performed on Finnish male smokers, 
hypothesized a protective effect of Vitamin E on ALS risk, by measuring serum concentrations on a 
long, double-blind, placebo-controlled trial (Michal Freedman et al. 2013). However, using Vitamin 
E in addition to Riluzole therapy, was not effective in extending survival in ALS patients, although an 
improvement in rate deterioration function was observed (Desnuelle et al. 2001). Polyunsaturated 
fatty acids are another class of antioxidants associated to a lower risk of ALS, possibly because they 
are capable to modulate lipid metabolism and inflammatory processes (Veldink et al. 2007; 
Fitzgerald et al. 2014). 
On the basis of clinical data, there is the impression that ALS patients have higher levels of 
physical fitness and thus a body mass index (BMI) lower than average (Huisman et al. 2013). Low 
BMI and malnourishment have been associated with shorter survival (Bouteloup et al. 2009). 
Conversely, overweight and obese subjects show a reduced risk to develop ALS (O’Reilly et al. 2013). 
Thus, increased fat and cholesterol intake may represent a protective factor (Paganoni and Wills 
2013). Other evidences stem from different studies assessing that high carbohydrate and low fat 
intakes are associated with higher ALS risk (Okamoto et al. 2007). Finally, a 10 year follow-up study 
reached the conclusion that high fat content is associated with a lower risk of developing ALS (Gallo 
et al. 2013). 
Physical exercise 
Before showing symptoms of the disease, ALS patients often show high levels of physical fitness. It 
is well known that one of the first well described ALS affected patient is Lou Gehrig, a famous 
baseball player of the beginning of the 20th century (Lewis and Gordon 2007). Furthermore, media 
have always raised the attention on sport celebrities who developed ALS at the top or near the end 
of their career. In consequence, much interest was raised on the hypothesis that physical activity 
could be a risk factor for developing ALS (Al-Chalabi and Hardiman 2013). Several studies have 
shown that - before symptom’s onset - subjects that developed ALS were leaner than healthy 
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controls, and that many performed semi-professional sport activities during their college years 
(Scarmeas et al. 2002).  
However, despite self-reported physical activity well correlated to objectively measured data, 
other studies showed no significant excess of extreme exercise in premorbid period of ALS patients 
(Huisman et al. 2013) and no dose-response relationship between physical activity and ALS could be 
assessed. Indeed, it seems to be that athletic prowess and ALS risk are two distinct aspects of a 
particular predisposition that confers both athletic advantage and increased risk of 
neurodegeneration (Al-Chalabi and Hardiman 2013). Furthermore, ALS is a pathological condition 
usually expressing in a period of life when other diseases of advanced age manifest. Consequently, 
those people affected by ALS are usually those that did not die by cancer or heart diseases, among 
which is likely to find subject who in the previous years exercised and had a better fit (Sutedja et al. 
2011). A higher incidence of ALS cases has been described among football players in the top Italian 
professional leagues and this may support the involvement of physical exercise. Other proposed 
causes may be soccer specific trauma or micro trauma, the use of illegal toxic substances or chronic 
misuse of drugs and dietary supplements, as well as exposure to pesticides used on playing fields 
(Vanacore et al. 2006). However, thus not excluding a potential effect of several factors acting 
together, conclusive scientific evidence of a link between ALS and soccer (or other professional 
sports) is lacking. 
Occupation 
Possible occupations where workers may be subjected to a higher risk to develop ALS include 
veterinarians, athletes, hairdressers, power-production plant operators, and armed forces 
personnel (Al-Chalabi and Hardiman 2013). However, no causal factors have been identified and 
common denominators among such different occupations are hard to identify. Several studies 
highlighted that US army personnel, especially those deployed in the Gulf Wars, were at risk for 
developing ALS. Soldiers are exposed to various potential harmful agents such as trauma and toxic 
substances (heavy metals and chemicals). However, drawing conclusions as for the role of military 
service in the etiology of ALS seems premature (Beard et al. 2016).  
Electric shock 
Magnetic fields, electrical fields, contact currents, micro shocks, and both perceptible and 
imperceptible electric shocks all contribute to occupational exposure to extremely low frequency 
electromagnetic fields (EMF) (Ingre et al. 2015). Higher risk of ALS has been associated to workers 
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involved in occupations leading to electric exposure (Vergara et al. 2013). The hypothesis that 
electric shocks are linked to ALS is intriguing because of the effects of electricity on the 
neuromuscular system, and the assumed excitotoxicity that would follow. However, evidence of a 
causative relationship is poor (Al-Chalabi and Hardiman 2013). 
Pesticides and chemicals 
Many pesticides are known to be neurotoxic at high levels and substances as organophosphates 
have a direct effect on the lower motor neuron synapse due to their ability to inhibit acetyl 
cholinesterase, the enzyme responsible for terminating the biological activity of acetylcholine. Most 
of these compounds are able to induce oxidative stress, mitochondrial dysfunction and neuronal 
loss. The main pesticides for which exposure is frequent, not only in professional workers as farmers, 
are insecticides, fungicides, herbicides and rodenticides (Bozzoni et al. 2016). Several reviews and 
meta-analyses associated pesticides exposure to increased ALS risk with different strengths (Sutedja 
et al. 2009; Kamel et al. 2012; Malek et al. 2012; Capozzella et al. 2014). Again, interaction of 
genetics with environment may play an important role. High interest was posed in evaluating the 
role of the paraoxonase gene cluster (PON) coding for enzymes able to detoxify organophosphate 
pesticides. Some PON1 polymorphisms have been identified as involved in lowering enzymatic 
activity. It is possible that PON1 mutation predisposes to ALS by reducing pesticide hydrolysis and 
promoting oxidative stress processes. There are strong evidences indicating a role for pesticides in 
ALS, as well in other neurodegenerative diseases, for which the association is more clearly 
established (Bozzoni et al. 2016). 
Metals 
The role of metal influence in ALS following environmental and/or occupational exposure has long 
been studied. Evidences that metal metabolism may be impaired in other neurodegenerative 
diseases like Alzheimer disease, Parkinson disease, neurodegeneration with brain iron accumulation 
(NBIA), multiple sclerosis, Huntington’s disease, Wilson’s disease, Menkes disease, and Friedreich’s 
ataxia all strongly supported this hypothesis and promoted studies in this direction (Roos et al. 2006; 
Rouault 2013). However, taken together, the studies performed in order to dissect metal 
contribution to ALS produced inconsistent results, probably due to limited exposure assessment 
(Sutedja et al. 2009). The samples analyzed were very heterogeneous, spanning from serum, to 
Cerebrospinal Fluid (CSF) to hair, to neuronal cells (Pamphlett and Kum Jew 2013; Roos et al. 2013; 
Bocca et al. 2015). In addition, exposure to metals is highly dependent on the environment, so that 
selecting a proper cohort of subjects and controls is crucial. Accordingly, another factor to lead to 
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inconsistent results could be the inclusion in the study of groups of subjects originating from 
different geographical areas. 
Transition metal induced toxicity has been proposed to be involved in the pathology (Carrì et 
al. 2003) and higher concentrations of metals and proteins that regulate metal homeostasis have 
been described in ALS patients (Goodall et al. 2008; Nadjar et al. 2012; Roos et al. 2013). Several 
studies have shown a deregulated homeostasis of metals like Fe, Cu and Zn in ALS; a deleterious 
effect of Zn on TDP-43 expression also has been demonstrated (Caragounis et al. 2010). 
Accumulation of these elements in motor neurons could exacerbate the oxidative stress, 
responsible for the cell death. However, it is not clear whether deregulation of these elements is a 
cause or a consequence of the pathology. 
Lead (Pb) is a well-known neurotoxic element that can cause neuropathies with the 
involvement of motor nerves (Oskarsson et al. 2015) and its association with ALS is a long-standing 
hypothesis. Lead levels in bone and blood were associated with ALS (Kamel et al. 2002 and 2003). 
Blood lead levels reflect environmental exposition, but are also influenced by the mobilization of 
lead from bones. Lead accumulates in human bones over the course of a lifetime, making them a 
possible endogenous source of Pb (Bocca et al. 2015). A study that considered also lead turnover 
from bone adjustment, still described higher levels of this element in ALS patients (Fang et al. 2010). 
However, the connection between lead and ALS is still unclear. Many of the lead-related studies 
have described also prolonged survival in patients with ALS with high lead levels. This led to the 
intriguing - but questionable - hypothesis that lead may represent a risk factor for developing ALS 
and a protective factor that slows ALS disease progression (Oskarsson et al. 2015). 
Manganese (Mn) toxic properties are known, as well its ability to cross the blood brain barrier 
and to accumulate in nervous tissues, prolonging its half-life (Dobson et al. 2004). Occupational 
exposure is documented in welders, that may present motorial deficit symptoms (Bowler et al. 
2006). Data on the association between Mn and ALS are quite scattered (Hozumi et al. 2011; Roos 
et al. 2013; Garzillo et al. 2014; Kihira et al. 2015). The heterogeneity of the results obtained in these 
studies may depend on the type of analysis, the tissue that was chosen, and the selection of the 
population involved in the study. 
Mercury (Hg) in all its forms (elemental, inorganic, and organic) has neurotoxic properties due 
to its ability to interfere with the glutathione pool, to damage mitochondria, and to enhance 
oxidation of lipids, proteins and DNA, all relevant factors in ALS etiology (ATSDR 1999; Carocci et al. 
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2014). In the case of Hg too, literature is insufficient to draw definitive conclusions. The association 
with ALS could be difficult also because exposure to high levels of Hg may lead to develop 
neurological and motorial symptoms that resemble ALS pathology. 
Iron (Fe) is the most abundant transition metal in human body, and an important cofactor in 
many biological processes like oxygen transport to tissues and oxidative phosphorylation in 
mitochondria. Given its importance and its toxicity as a potential catalyst of the formation of ROS 
species, its metabolism is very finely tuned. Different studies showed a correlation between high 
serum ferritin levels and ALS, probably reflecting general iron overload (Goodall et al. 2008; Nadjar 
et al. 2012). Other neurodegenerative disorders are characterized by iron accumulation with 
concomitant deregulation of iron homeostasis (Hadzhieva et al. 2014). Among ALS patients, 
increased iron concentration has been reported in the ventral spinal cord and in the motor cortex 
(Kasarskis et al. 1995). 
Exposure to selenium (Se), and particularly to its inorganic forms, has been hypothesized as a 
risk factor for ALS. Selenium is an essential element and its biological activity mostly depends on its 
chemical form. Inorganic selenium is indeed more toxic than the organic species (Vinceti et al. 2010). 
The suggestion that selenium may be involved in ALS raised from the study of a cluster of patients 
resident in a seleniferous area of South Dakota (USA), and from an Italian study that extensively 
investigated a well-defined ALS case series of residents of the Emilia-Romagna region (Kilness and 
Hochberg 1977; Vinceti et al. 1997; Vinceti et al. 2010). A study performed on selenium species in 
the Italian cohort found an association of increased ALS risk with higher concentrations in CSF of 
inorganic selenium, as selenite, and of human serum albumin-bound selenium, confirming results 
obtained in a cohort from Norway (Roos et al. 2013; Vinceti et al. 2013). How and whether these 
findings may be generalizable to other populations seems to deserve further investigation (Ingre et 
al. 2015). 
Aluminum (Al) can easily cross the blood/brain barrier and reach the brain, where it can 
accumulate after chronic exposure. High levels of Al in the brain may activate glial cells to produce 
inflammatory cytokines and ROS, possibly leading to neuronal cells loss (Becaria et al. 2002). These 
effects were confirmed after studies on animal models, with a particular focus on motor neuronal 
degeneration (Tanridag et al. 1999; Kihira et al. 2002). In studies performed on ALS patients, Al was 
found slightly increased in the blood of patients respect to controls, decreased in patients' hair 
(Bocca et al. 2015), and increased in CSF (Roos et al. 2013). Other reports did not detect differences 
in Al concentrations between patients and heathy controls (Bergomi et al. 2002; Garzillo et al. 2014). 
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Other metals with potential relevance for ALS are copper, arsenic, cadmium, cobalt, zinc, 
vanadium, and uranium, all of which have been found in significantly elevated concentrations in the 
CSF of ALS patients when compared with healthy controls (Roos et al. 2013). In conclusion, single 
metal evaluations may underestimate their relevance for health risks. It is more likely that all these 
metals interact with one another with an additive or even a synergistic effect (Andrade et al. 2015). 
In consequence, it is important to consider the possible complex interactions between single metals 
in evaluating their potential association with ALS as it has been demonstrated, for instance, that a 
mixture of arsenic, cadmium and lead has the ability to compromise blood brain barrier, by acting 
with synergistic toxicity (Rai et al. 2010). 
 
Biomarkers 
Biomarkers are defined as objectively measurable parameters that can be used as an indicators of 
a biological condition or the effect of a treatment (Bowser et al. 2006). To be applied to diagnostic 
procedures, such as predicting disease susceptibility, monitor disease progression or evaluating 
therapies’ toxicity (Figure 6), biomarkers must have high levels of sensitivity and selectivity (Ryberg 
and Bowser 2008).  
 ALS still lacks of diagnostic tests and its diagnosis is usually late; however, the fast 
developments in proteomics may facilitate the discovery of new protein biomarkers that could also 
help in providing insights in the pathogenic mechanisms of the disease. Prognostic biomarkers could 
further indicate different stages and modifiers of disease progression (Krüger et al. 2013). 
 
Fig. 6. Disease key clinical events and their relation to different types of biomarkers (Ryberg et al. 2008). 
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Blood and cerebrospinal fluid (CSF) are the most accessible biofluids. The disadvantage relies 
in the fact that a potential protein biomarker released from a specific cell type, would be necessarily 
diluted in the large volumes of blood or CSF: it would also be of difficult detection and may reflect 
processes different from what it is interested. Indeed, biochemical constituents of these body fluids 
may be altered also by secondary pathological effects. 
Plasma and serum are the preferred biofluids for biomarkers discovery and a wide number 
of researches pointed to find out one or more circulating protein biomarker. However, it often 
resulted in conflicting and inconclusive results mostly due to differences in analytical assays and 
samples together with small study group sizes. Proteins investigated as serum biomarkers belong to 
several different groups, such as growth factors or hormones, cytokines and other inflammatory 
proteins, but also enzymes and enzyme inhibitors (Ryberg and Bowser 2008). 
 CSF is an important source for proteomic-based biomarker research, since it represents a 
diagnostic window to the central nervous system. However, high invasiveness, heterogeneous 
sampling volume and low protein abundance represent a considerable limit. Anyhow, due to 
functional and physical proximity of motor neurons to CSF, it may better reflect protein abundance 
alterations than other body fluids (Krüger et al. 2013). CSF biomarkers candidate can be classified 
into inflammatory markers, glial response markers, axonal damage and apoptosis markers (Tumani 
et al. 2008). 
The state of art of all the current studies related to the research for biofluids biomarkers in 
ALS is excellently presented by Krüger et al. and by Robelin and De Aguilar in their recent reviews 
(Krüger et al. 2013; Robelin and Gonzalez De Aguilar 2014). 
Finally, ALS diagnosis is strongly hampered also from the wide heterogeneity of its 
phenotype. Thus, it could be more effective to apply a concerted set of biomarkers or to assess the 
ratio of different proteins, instead of focusing on a single biomarker, that could be not so specific 
for discriminating the disease from other pathological conditions. 
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Therapy 
At present, no therapy is available to treat ALS. Treatment of patients is mostly symptomatic, aimed 
at improving quality of life and maintaining patient’s autonomy as long as possible. Dysphagia is a 
common symptom, leading to malnutrition, weight loss and dehydration. Malnutrition is usually 
associated to a worsened prognosis and to a reduced survival. When autonomous nutrition is no 
longer possible, percutaneous gastrostomy is recommended (PEG). When respiratory muscles 
become too weak, the intervention with artificial breathing machines to support ventilation is 
required (Kiernan et al. 2011).  
The only available drug, approved by the Food and Drug Administration (FDA), is Riluzole. It is 
a neuroprotective compound whose efficacy is to extend survival (typically, 3/6 months) and to 
delay the intervention with artificial breathing (Leigh et al. 2003). However, Riluzole has no effects 
on motor and pulmonary function, and it is ineffective when treatment is done in the last stages of 
the disease (Rowland and Shneider 2001). Riluzole acts as a blocker of calcium channels. It activates 
potassium channels, inhibits dopamine and acetylcholine release, and blocks GABA reabsorption. 
Riluzole ability to lower presynaptic glutamate release makes it able also to control excitotoxicity 
(Wijesekera and Leigh 2009). 
At present, the most promising therapeutic targets are excitotoxicity, oxidative stress and 
neurotrophic factors modulation. Gene and stem cells therapy represent the newest and most 
promising approaches to treat the disease, although clinical trials are still needed for assessing their 
safety and efficacy.  
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AIM OF THE STUDY 
ALS is a complex disease in which genetics and environmental factors interplay in different and still 
unknown proportions, both in giving rise to the pathology and in modifying the clinical phenotype. 
The study of geographical clusters of ALS patients, such as those described in the Western Pacific 
region, has been helpful - in the past years - to get more insights into the pathology. In medical 
terms, a cluster is a “mini-epidemic” distribution of a pathological condition within a well-defined 
region, where it accounts for a higher-than-expected disease prevalence (i.e., above the estimated 
national prevalence) (Malaspina et al. 2002). Studying individuals exposed to the same 
environment, thus ideally subjected to the same exogenous stressors, could be very valuable by 
limiting one of the most confounding variables in ALS studies. Indeed, a diverse environmental 
exposure is almost always necessarily present when analyzing the large cohorts of patients that are 
usually required to reach statistically significant numbers of cases in epidemiological-type studies. 
 This PhD thesis presents a multidisciplinary study performed on a small cohort of sporadic ALS 
patients, all originating from a restricted and defined geographical area. Focusing on a very limited 
geographical area, gave the chance to consider the characteristics of the surrounding environment 
and allowed to raise hypotheses on the possibly involved stressors acting on the local population, 
being those environmental or dietary contributions. 
 The study area includes four municipalities – Casarza, Lavagna, Cogorno and Sestri Levante – 
with a total population of about 36,000 individuals over an area of 83.5 km2, located between two 
narrow mountain valleys and the Mediterranean seaside, belonging to the Genoa district of the 
Liguria region in northwestern Italy. ALS point prevalence in the Liguria region is 7.85/100,000 (95% 
CI 6.54–9.36) people (Scialò et al. 2016). The study enrolled seven patients (4 men and 3 women) 
and five controls (2 men and 3 women, age-matched with the patients (69 ± 12 years vs. 64 ± 6 
years) and living in the same geographical area). Besides the seven patients enrolled in our study, 
we are aware of the presence of additional affected subjects, making prevalence of ALS in this area 
markedly higher than in the rest of the region. 
 To overcome the obvious limits related to the small number of subjects necessarily involved 
in this study, advantage was taken from the application of a multifactorial statistical evaluation, 
based on a machine learning software. This software, belonging to the artificial neural networks 
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architecture, was specifically designed to analyze complex problems, where the number of variables 
significantly exceeds the amount of subjects involved in the study, as usually is in the case of rare 
diseases. These approaches had been successfully applied in previous studies of a complex disease 
such as ALS (Buscema et al. 2012). 
In this multidisciplinary work two main lines of research were followed. Although both rely on 
assessing specific components in the blood of patients and controls, these two lines are 
methodologically distinct and provide independent information (Figure 7).   
 A first research line aimed at investigating the role of circulating metals in both serum and 
whole blood, trying to point out differences in metals’ levels between ALS patients and healthy 
control subjects. The analytical data were processed to unravel possible associations with clinical 
features of the disease, eating habits, and DNA oxidative damage. Data on environmental pollution 
were not collected in this study, but the presence of a mine within this area led to focus the 
investigations firstly on the already proposed role of metals in ALS. This Cu and Fe mine, closed in 
1962, is located 8 km inland from the study area, within the basin of a creek, whose waters are 
reported to be strongly polluted due to Acid Mine Drainage. Waste rock dumps can store significant 
amounts of potentially deleterious metals that can be released to solutions during transformation 
processes, induced by variations in the physicochemical parameters or by ageing. This could lead to 
the release, to the circulating solutions, of high amounts of potentially toxic metals during 
weathering of primary sulfide ores (Fe, Cu, Zn, etc.) and of the accompanying mine tailings (Cr, Ni, 
V, etc.) (Marescotti et al. 2010). 
 The other line of research pointed at evaluating the serum proteome, and used bi-dimensional 
electrophoresis (2DE) as the main approach. Despite 2DE being an already mature methodology, 
literature data on ALS subjects are still scarce. This research aimed at describing the serum 
proteome of this peculiar group of patients, with a particular focus on possible disease biomarkers, 
actually badly needed for diagnostic purposes. ALS diagnosis is usually difficult and may take up to 
16 months from the onset of the symptoms (Kraemer et al. 2010). Only the identification of selective 
and sensitive biomarkers could allow an earlier diagnosis, which would in turn lead to a better care 
of the patients, since it is by now clear that the timelier the treatment with Riluzole, the more 
successful its outcome. The availability of usable biomarkers would be most valuable also in clinical 
trials, in which at present the only meaningful indicator is the survival rate (Robelin and Gonzalez 
De Aguilar 2014). In this perspective, great efforts have been made during the last years for 
identifying possible biological markers and risk factor indicators, including different proteomic 
35 
 
investigations on tissues of different availability (Dengler et al. 2005; Ranganathan et al. 2005; 
Brettschneider et al. 2008; Brettschneider et al. 2010; Nardo et al. 2011; Forseen and Corey 2012; 
Collins et al. 2015; Chen et al. 2016). However, heterogeneity of investigated biological samples and 
technologies applied, hampered the definition of conclusive results.  
 Finally, the proteomic analysis was integrated by the evaluation of ALS associated genes that 
resulted relevant from these experiments. This work is, at present, the first attempt to describe the 
serum proteome of a geographic cluster of ALS patients, with the aim of limiting the variability, 
necessarily present in the cohorts of subjects described in literature, in the most accessible 
biological sample. 
The multidisciplinary approach applied in this study was possible due to the limited number of 
subjects involved. This, in turn, gave the opportunity to consider simultaneously different aspects 
of this pathology, trying to get a more comprehensive understanding of the disease. 
 
Fig. 7. Schematic representation of the design of the study presented.  
36 
 
MATERIALS AND METHODS 
Blood sampling 
Blood was collected in a vial for serum separation and in two vials for whole blood and genetic 
analyses. Sampling was performed after an overnight fast and, after clotting, serum was separated 
by centrifugation at 3000 rpm for 15 minutes. Aliquots of serum were stored at -80°C. Vials for whole 
blood analyses were stored at -80°C without any treatment. To minimize contamination during 
blood sampling, the vials to be used for trace metal analysis were the last ones collected. 
Nutrition survey 
Both patients and controls were administered a survey to collect information about lifestyle and 
nutrition habits. The questionnaire mostly focused on intake of several foods with frequency 
indication assessed as: never, once a week, two or three times a week, every day. Patients were 
instructed to fill the questionnaire with reference to their eating habits before the disease onset. 
Inductively Coupled Plasma - Mass Spectrometry 
Inductively Coupled Plasma - Mass Spectrometry (ICP-MS) is a technique used for elemental 
determinations with high detection capability for rare elements at concentrations as low as one part 
in 1015 (ppq). The instrument combines a high-temperature inductively coupled plasma source - that 
converts the atoms of the sample’s elements in ions - with a mass spectrometer that separates and 
quantify those ions. An inductively coupled plasma is a plasma made by partially ionizing argon gas 
(Ar → Ar+ + e−), energized by inductively heating the gas with an electromagnetic coil, and containing 
a sufficient concentration of ions and electrons to make the 
gas electrically conductive. Ions extracted from the plasma 
flow, through a series of "cones", into a mass spectrometer, 
usually a quadrupole. Separation of ions occurs on the basis 
of their mass-to-charge ratio and a detector receives an ion 
signal proportional to the concentration. The concentration 
of a sample can be determined through calibration with a 
certified reference material, such as a single or a multi-
element reference standard. For the analyses of both serum 
and whole blood samples, 45Sc, 89Y and 159Tb were used as 
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internal reference at a final concentration of 20 μg L-1, and were added to other samples from a 
stock 2 mg L-1 solution. 
Serum samples were diluted 1:20 with 0.05% Triton X-100 in MilliQ water. Typical analytical 
interferences were removed by using Collision-Reaction-Interface (CRI) with an H2 flow of 70 mL 
min-1 through the skimmer cone. SeronomTM Trace Elements Serum L-1 and L-3 were used to build 
appropriate calibration curves. Samples of whole blood were diluted 1:100 with 1.3% HNO3 and 
0.05% Triton X-100 in MilliQ water. Since whole blood has a pronounced matrix effect, the standard 
addition method illustrated above was used to control and validate the results. Typical analysis 
interferences were removed by using CRI, but in this case the H2 flow through the skimmer cone 
was increased to 93 mL min-1. SeronomTM Trace Elements Whole Blood L-3 was used to control and 
validate the results. 
Two-dimensional Electrophoresis  
Two-dimensional gel electrophoresis (2DE) is a well-known technology and a very valuable, 
powerful and widely used method to assure resolution and pattern recognition for the analysis of 
complex protein mixtures extracted from cells, tissues, or other biological samples. Furthermore, it 
provides a very wide spectrum of customizable solutions with minimal changes in the work pipeline. 
This technique separates proteins in two steps, Isoelectric Focusing (IEF) and SDS-
polyacrylamide gel electrophoresis (SDS-PAGE). The first-dimension (IEF) run separates proteins 
according to their isoelectric points (pI), while the second dimension consists in a SDS-PAGE that 
separates proteins according to their molecular weight (MW) (Figure 8 and 9):  
A. The sample, composed by a heterogeneous mixture of proteins, is placed close to the 
electrode, at one end of a strip with a gradient of pH. 
B. At the end of the IEF run the proteins have migrated and stopped at their pI, where they have 
no electric charge. Proteins of different sizes may migrate at the same pI. 
C. After the equilibration step, each protein is coated with SDS, that confers a homogeneous 
negative charge per mass unit. 
D. To run the second dimension, the IEF strip is set to the top of a SDS-PAGE gel where proteins 
are separated according to their size and thus to their molecular mass. 
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Fig. 8.  Schematic representation of 2DE (Rabilloud and Lelong 2011). 
 
Immobilized pH Gradient (IPG) strips were prepared following the procedures described in 
The Protein Protocols Handbook (Walker 2009). A Non Linear (NL) IPG in the 4-7 pH range was 
prepared by mixing appropriate volumes of 0.2 M Acrylamido Buffers with different pKa values 
(available from Sigma-Aldrich), acetic acid 1 M (Sigma-Aldrich), T30C4 acrylamide stock (BioRad), 
ammonium persulfate solution (Sigma-Aldrich), N,N,N′,N′-tetramethylethylenediamine (BioRad) 
and glycerol (Merck). After polymerization at 50°C for 1h, the slabs were washed in 1% glycerol for 
an additional hour. After drying, the gel was rehydrated in a solution of 8 M Urea containing 0.5% 
carrier ampholytes in the 4-7 pH range. Gel strips 16 cm x 0.8 cm in size were cut for individual 
sample loading. Serum aliquots corresponding to 600-700 μg of proteins were loaded near the 
cathode, with or without the addition of 1% 2-mercaptoethanol, depending on whether reducing or 
non-reducing conditions were desired. Reducing and non-reducing conditions optimize the 
resolution of different sets of proteins over a crowded area of the 2DE map of human serum, so that 
their combined use enhances the potential for an accurate quantitative evaluation of most serum 
proteome components (Wait et al. 2005).  
IEF was run in a Multiphor II horizontal electrophoretic chamber with movable electrodes 
(Amersham Bioscience). The electric conditions were: 1 h at 200 V, 1 h at 300 V, 1 h at 400 V, 1 h at 
500 V, 1 h at 600 V, 700 V overnight, 1 h at 2000 V and 1 h at 3000 V. After equilibration in 2% SDS,  
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Fig. 9. Workflow of how 2D gel electrophoresis is used in a proteomics analysis(Rabilloud and Lelong 2011) 
 
with or without the addition of 1% 2-mercaptoethanol, SDS-PAGE was run on individual strips 
in slab gels consisting of a 7.5-17.5% T gradient polyacrylamide gel cast in Laemmli buffers (Laemmli 
1970), at 75 mA per gel. Image analyses of the Coomassie Blue stained patterns were carried out 
with Image Master Software ver. 5.0 (Amersham Biosciences). The gel with the highest number of 
spots among controls and patients was designated as the reference. The remaining gels were 
matched to the reference in order to identify the differences in spot volume (absorbance integrated 
over area). Most of the spots were automatically matched across gels by the software; the 
correctness of each matching was checked manually adding, where needed, “de novo” spots. In 
order to minimize any possible variation that might have been caused by differences in loading, 
staining, and destaining, the volume of each protein spot on a 2DE gel was normalized by computing 
its percentage over the total protein volume in that gel. 
Mass spectrometry identification of proteins from 2 -DE gels 
The gel pieces were firstly washed and destained by two sequential rinses with 25 mM NH4HCO3 
and 50% v/v aqueous acetonitrile (ACN), followed by washing them three times with a 1:2 mixture 
of ACN and 50 mM NH4HCO3. Finally, the gel pieces were completely dehydrated with 100% ACN, 
and the solvent removed in a SpeedVac for about 20 min. Samples removed from the SpeedVac 
were treated with a small volume of trypsin (Promega, Milan, Italy, 12 µg mL-1 in 50 mM NH4HCO3). 
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After trypsin absorption (30 minutes on ice) the gel pieces were completely covered with a few 
microliters of 50 mM NH4HCO3 and incubated overnight at 37°C. Formic acid (0.1% final 
concentration) was used to stop trypsin activity. 
The samples were then analyzed by means of LC-ESI-MS/MS. MS spectra were acquired on a 
hybrid quadrupole orthogonal acceleration time-of-flight (Q-Tof) mass spectrometer (SYNAPT-MS 
G1, Waters Corporation, Milford, MA, USA) equipped with a TRIZAIC source and connected to a 
nanoACQUITY UPLC system. The samples were injected onto a TRIZAIC nanoTile (Acquity HSS T3, 
Waters Corporation, Milford, MA, USA), that integrates a trapping column (5 μm, 180 μm x 20 mm) 
for desalting and an analytical column (1.8 μm, 85 μm x 100 mm) for highly reproducible peptide 
separation. The elution was performed at a flow rate of 450 nL min-1 by increasing the organic 
solvent concentration from 3 to 40% B in 30 min. Solvent A was 0.1% formic acid in water, and 
solvent B was 0.1% formic acid in ACN. The TOF analyzer was externally calibrated using [Glu1]-
fibrinopeptide B from 50 to 1990 m/z. Data were post-acquisition lock-mass corrected, using the 
monoisotopic mass of the doubly charged precursor of [Glu1]-Fibrinopeptide B (m/z 785.8426) 
infused into the mass spectrometer at a flow rate of 100 nL min-1 through a NanoLockSpray interface 
using the auxiliary pump of the nanoACQUITY system. A survey scan over the m/z range of 350-1990 
was used to identify protonated peptides with charge states of 2, 3 or 4, automatically selected for 
data-dependent MS/MS analysis (MassLynx v 4.1 SCN833, Waters Corporation, Milford, MA, USA). 
All raw MS data were processed with ProteinLynx Global SERVER software (PLGS v 2.5.1, Waters 
Corporation, Milford, MA, USA) and the proteins were identified by correlating the interpreted 
spectra with entries in UniProt database.  
The UniProt database (release 2015-3; number of human sequence entries, 20199) was used 
for database searches of each run. Carbamidomethylation was considered as fixed modification and 
methionine oxidation as variable, one missed cleavage per peptide was allowed. The mass tolerance 
window was set at 25 ppm for peptide precursors and 0.05 Da for fragments. In parallel, the spectra 
were also searched against the Uniprot database by using Mascot (Matrix Science, London, UK). 
Valid identification required two or more peptides independently matching the same protein 
sequence, with a significant peptide score (higher than the identity score from Mascot). 
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Comet assay  
The level of oxidized DNA bases was determined through the comet assay, by assessing the sites 
sensitive to formamido-pyrimidine DNA glycosylase (FPG), which detects oxidized purines, primarily 
8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG) and ring-opened formamido-pyrimidine 
nucleobases. The standard protocol for the evaluation of DNA damage is performed in peripheral 
blood mononuclear cells. Recent studies reported the possibility to use also frozen whole blood 
(Akor-Dewu et al. 2014). In the present study, only aliquots of frozen whole blood samples were 
available for the evaluation of DNA damage; thus, the protocol was highly standardized and 
performed according to Akor-Dewu et al. with slightly modifications.  
Aliquots of whole blood (5 μl, thawed from frozen stock at -80°C) were mixed with Low 
Melting Point (LMP) agarose (1.5% wt/vol) in Tris/acetate-EDTA buffer at pH 7.4 at 37°C and 
immediately pipetted onto a frosted glass microscope slide (Richardson Supply Co., London, UK) 
precoated with a layer of 1% (wt/vol) Normal Melting Point (NMP) agarose in Tris/acetate-EDTA 
buffer. The following steps were performed as previously described (Del Bo’ et al. 2015). For each 
sample, two slides were prepared. Cells were lysed by placing the slides in a lysis buffer (2.5 M NaCl, 
0.1 M Na2EDTA, 10 mM Tris, 1% Triton X-100, 1% DMSO, and 1% N-lauroylsarcosine sodium salt, pH 
10) for 1 h at 4°C in the dark. Then, slides were washed three times in a buffer solution (40 nM 
HEPES, 0.1 M KCl, 0.5 mM EDTA and 0.2 mg ml-1 bovine serum albumin, pH 8) and successively, 
incubated for 45 min at 37°C with buffer containing FPG (100 ng ml-1). FPG was omitted in control 
runs. The slides were then placed in an alkaline solution (0.3 M NaOH, 1 mM Na2EDTA) for 40 min 
at 4°C in the dark. Electrophoresis was performed at 1.1 V cm-1 for 20 min. Slides were successively 
neutralized (0.4 M Tris/HCl, pH 7.5) for 15 min at 4°C in the dark, stained with ethidium bromide (2 
μg ml-1), washed in PBS, drained and coverslipped. One hundred images per slide were electronically 
captured using an epifluorescence microscope (Olympus CX 41; Olympus Italia) attached to a high-
sensitivity CCD video camera (CFW 1808M; Scion Corporation, Germany) coupled to an image 
analysis system (Cometa 1.5; Immagini e Computer, Bareggio, Milan, Italy). For each sample, the 
percentage of DNA in the tails of control cells (not treated with FPG) was subtracted from that in 
tails of the FPG-treated cells. 
Genetic analyses 
Genomic DNA was extracted according to standard procedures (Miller et al. 1988). Coding exons 
and intron-exon boundaries of the SOD1 gene, exons 5, 6, 13, 14 and 15 of the FUS gene, exon 6 of 
the TARDBP gene, an amplicon containing both rs429358 (C112R) and rs7412 (R158C) from the 
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APOE gene, one including rs854560 (L55M) and another with rs662 (R192Q) from the PON1 gene 
were ampliﬁed through PCR (Veriti™ Thermal Cycler, Applied Biosystems™, Waltham, MA, USA), 
sequenced (Big-Dye Terminator sequencing kit 1.1 or 3.1, Applied Biosystems™, Waltham, MA, USA) 
and run on an ABIPrism 3730 genetic analyzer. An amplicon containing rs7493 (S311C) from the 
PON2 gene was PCR amplified and digested with DdeI enzyme; the presence of the polymorphism 
abolishes a cut site for the restriction enzyme. The product of digestion reaction was loaded on a 4 
% agarose gel and run at 70 V for 3 hours. In the presence of the polymorphism only two bands (207 
bp + 33 bp) were present, whereas the wild type sequence was cut in two sites, yielding three bands 
(140 bp + 67 bp + 33 bp). 
 The possible presence of the G4C2 hexanucleotide repeat expansion in the ﬁrst intron of 
C9ORF72 was evaluated with fragment length analysis. This technique consists in a PCR performed 
with two primers, flanking the region where the G4C2 expansion is present. One of the two primers 
is labeled with the fluorophore FAM (6-carboxy-fluorescein) at the 5’ end. If the pathological 
expansion is present (> 30 repeats), the amplification will not be possible, thus only one peak, 
corresponding to the wild type allele would be visible after capillary electrophoresis (Figure 10). For 
negative subjects two peaks will be present and the length of the non-pathological expansion (< 30 
repeats) can be calculated with the formula: [(length of the amplicon (bp) – 129)/6]+2 (129 bp is the 
size of the amplicon containing two hexanucleotide repeats) (DeJesus-Hernandez et al. 2011). Since 
none of the subjects presented the expansion, repeated primer PCR (RP-PCR), able to determine the 
length of the pathological expansion, was not performed.   
 
Fig. 10. Results of electrophoretic runs obtained through fragment length analysis: A) Heterozygous subject 
with two alleles within the normal range of expansion. B) Homozygous subject with an expansion within the 
normal range or heterozygous subject bearing a wild type allele and an expanded allele (not detectable). 
  
A B 
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Statistical analyses 
Classical statistics: 
Student’s t-test was applied to identify differences in the analytical data between patients and 
controls. Correlations between the variables and clinical data, such as disease duration, age at blood 
sampling and age at onset, were evaluated with Pearson’s and Spearman’s correlation coefficient 
and linear regression, performed using IBM SPSS Statistics Base 23 and Analyse-it software, version 
4.65.2. 
Artificial Neural Networks: 
Artificial neural network (ANN) 
analyses shift the paradigm of data 
analysis from forcing data into a pre-
constituted scheme, into a bottom-
up definition of the regulating 
processes, generated on the basis of 
the relations between data. This 
approach has been developed to 
analyze a complex system, that 
adapts itself at the environment 
during time. Thus, in this context, 
time is not a noise, but an 
evolutionary parameter. Health and 
diseases processes are based on complex networks of interacting elements (from genes to 
environment), that are the consequence of their regulatory dynamic processes (Figure 11). 
However, huge amount of data per subject hampered statistical tests. With this background it is 
evident that this approach applies perfectly to ALS. Indeed, it is really important to manage the 
complexity of this disease, from a statistical point of view, with tools able to handle this complexity 
of relations and data, rather than treating them with reductionist approaches, unable to disclose 
the hidden interactions that are supposed to predispose to the disease (Buscema et al. 2012). 
In this work, Auto Contractive Map (Auto-CM, based on ANN architecture) was used. This 
method allows to visualize the correlations among the variables by constructing a space where 
closeness reflects accurately their association. Indeed, closeness is visualized in a graph that 
Fig. 11. Comparison between classical computation approach 
and bottom-up approach (Capecchi et al. 2010). 
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highlights only the relevant correlations and presents a global picture of the whole pattern of 
associations. 
The Auto-CM software is organized with 
a three-layer architecture (Figure 12). 
Each layer contains an equal number of 
units, corresponding to the variables 
loaded by the user. In the input layer, the 
signal is captured from the environment, 
and in the hidden layer it is modulated 
inside the software. Through the output 
layer, Auto-CM feeds back on the basis 
of the stimuli received and processed. 
Connections between the input and the hidden layer are mono-dedicated, while those between the 
hidden layer and the output layer are at maximum gradient.  
The learning algorithm of the software may be summarized in two transfer steps (from input 
to hidden layer and from hidden to output layer), and two steps where adaptation of the values of 
the connections between the layers occurs. In conclusion, the matrix of the weights of each variable 
is transformed into a matrix of distances among the nodes in the final output graph. Generally 
speaking, a graph is a mathematical abstraction consisting of a set of vertices (V), and a set of edges 
(E), connecting two vertices in the graph, to which it is possible to associate scalar values (in this 
case, the distance). The graph represented in the output of Auto-CM elaboration is the Minimum 
Spanning Tree (MST). It represents the energy minimization state of a structure, thus, in this 
situation, the most probable state that the system tends to assume (Buscema et al. 2012). Indeed, 
it is what we could call the framework of any dataset. In the building of the MST only the connections 
that are really necessary to keep the system coherent are selected. Consequently, all the links 
included in the MST are fundamental, but, on the contrary, not every “fundamental” link of the 
dataset needs to be in it, since every link that gives rise to a cycle is eliminated. Consequently, to 
better capture the intrinsic complexity of a dataset, it is necessary to add more links to the MST by 
creating a Maximally Regular Graph (MRG). The MRG adds to the MST the most important 
relationships between the variables, to identify the graph with the maximum number of regular 
micro-structures inside the system, by adding back to the original MST, one by one, the missing 
connections previously skipped during the computation of the MST itself (Buscema et al. 2012).  
Fig. 12. An example of Auto-CM with four units 
(Buscema et al. 2012). 
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RESULTS AND DISCUSSION 
POPULATION SELECTION 
 
The study involved 7 patients (4 men and 3 women) and 5 controls (2 men and 3 women, age-
matched with the patients – 68.7 ±11.9 years vs. 63.7 ± 6.3 years) all living in the same geographical 
area (Table 2 and 3). Among the 12 subjects, 8 were born and lived in the reference area, one patient 
moved there in 1970, another in 1988; one control moved in at the age of 12. During the study one 
patient reported to have had the onset of the disease four years before moving in the geographical 
area of interest. However, at the moment of the blood sampling he was living in the area for seven 
years. Analyses already performed were reconsidered in the light of this new information, but 
results did not change.  
All patients were diagnosed with clinically defined sporadic ALS; in six of them onset was 
spinal, in one bulbar. The mean age at onset was 61.3 ± 7.8 years; the mean duration of disease, 
from onset to the time of blood collection, was 7.8 years (range = 2.1-19.1 years). All the patients 
are currently treated with Riluzole; two of them underwent PEG.  
All subjects enrolled in the study signed an informed consent, according to the guidelines of 
the Niguarda Ca’ Granda Hospital ethics committee. Simultaneously to the blood sampling and 
informed consent signing, all subjects underwent an interview concerning their eating habits, 
including the propensity at drinking bottled vs tap water. 
ID Gender 
Age at 
onset (y) 
Site at 
onset 
Duration of 
disease (y) 
PEG 
BMI at 
onset 
(m2Kg-1) 
Occupation Smoke 
1 SU M 48 LL 2.1 N 29.4 Shopkeeper N 
2 SU M 57 Bulbar 3.0 Y 23.0 Manager Y 
3 SU M 65 UL 3.2 N 28.1 Workman N 
4 SU F 60 LL 19.1 N 22.9 Seamstress N 
5 SU F 71 LL 12.1 N 27.9 Farmer N 
6 SU M 69 LL 11.0 N 23.7 Manager N 
7 SU F 59 LL 4.2 Y 29.3 Teacher EX 
Table 2: Minimum clinical data for ALS patients. LL: lower limbs, UL: upper limbs. Duration of disease is 
calculated as time passed from symptoms onset to blood sampling or PEG start. 
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ID Gender 
BMI 
(m2Kg-1) 
Occupation Smoke 
244 N F 20.8 Odontologist N 
245 N F 22.3 Teacher Y 
246 N F 25.7 Housewife EX 
247 N M 28.1 Professor N 
248 N M 31.1 Manager EX 
Table 3: Data for control subjects. 
Geographical area overview 
The study area includes four municipalities – Casarza, Lavagna, Cogorno and Sestri Levante – with a 
total population of about 36,000 individuals over an area of 83.5 km2. It is located between two 
narrow mountain valleys and the Mediterranean seaside, in the Genoa district of the Liguria region 
in northwestern Italy. ALS point prevalence in the Liguria region is 7.85/100,000 (95% CI 6.54–9.36), 
(Scialò et al. 2016), higher than what reported for the general Italian population (Chiò et al. 2013). 
Authors of this study suggest that this occurrence could be related either to a better case 
ascertainment in a relatively small area (5420 km2 with about 1,600,000 inhabitants) and/or to the 
demographic structure of Liguria, where about 28% of the population is over 65 years of age. Only 
on the basis of point prevalence reported for the Liguria region, in the area of interest we would 
expect to find 2.83 ALS cases, however we are aware of a markedly higher number of affected 
subjects. 
In the same area is documented the presence of the Libiola Fe-Cu sulfide mine, exploited until 
1962. During its activity the Libiola mine produced over 1 Mt of Fe-Cu sulfides (Marescotti et al. 
2012). The area of the mine lies within the drainage basin of the Gromolo Creek and two of its main 
tributaries (Figure 13), collecting mine waters. The whole mining area is subjected to intense Acid 
Mine Drainage (AMD) processes, involving the five major waste rock and tailings dumps and the 
remaining exposed unmined portions of the ore veins (Carbone et al. 2005a; Carbone et al. 2005b). 
This phenomenon leads to the acidification of the circulating waters, that are reported to have a pH 
< 3. This acidity of streams circulating in the mine galleries and within the rock deposits, leads to the 
alteration of the mineral assemblage of the rocks itself. For this reason, several studies report a very 
bad quality of the waters flowing from the mine, with very high levels of potential toxic elements 
(Fe, Cu, Zn, Ni, As, Cr, V, Ti, Al) (Dinelli et al. 2001; Marini et al. 2003). Most of the metals detected 
in the mine tailings and in ore-accompanying rocks, strongly exceed the limits for industrial and 
residential sites imposed by the Italian law (Legislative Decree n. 152, 3 Aprile 2006).  
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cFig. 13. Location of the Libiola mine 
site. In the magnification: geographic 
distribution of subjects involved in the 
study, with reference to the water basin 
borders. 
Elaboration of the figure from 
Roccotiello et al. 2015. 
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NUTRITION SURVEY 
 
An exploratory questionnaire was submitted to the subjects involved in the study. All of them were 
instructed as for filling the survey. In particular, ALS patients were asked to recall information on 
nutrition habits in the time period before the onset of disease. Information about occupation, 
smoking habits, body mass index (BMI) and use of tap vs bottled water to drinking purposes were 
also collected. 
 The section regarding nutrition took account of the frequency intake of several foods: cookies, 
croissant, rusks, bread, crackers, pasta or rice, red meat, white meat, legumes, potatoes, fish, egg, 
cold cuts, fresh cheese, ripened cheese, vegetables, fruits, sweets, pizza (Table 4). The aim of the 
survey was, besides collecting information, to assess if there were differences in the diet of ALS 
subjects and healthy controls and/or provide information as for whether the consumption of one 
or more foods were associated to the disease status. 
 Auto-CM software was used to analyze the results. There were no evident differences in the 
nutrition habits of ALS subjects with respect to healthy controls. The MST built according to the 
answers reported in the questionnaire does not show any clustering of patients or controls (Figure 
14 A). This leads to concluding that there is no significant combination of foods able to discriminate 
between the two groups, since all subjects represented in the output graph are mixed. Furthermore, 
the high complexity of interactions shown in the MRG highlights that the subjects involved in the 
study are highly interconnected, thus sharing common nutrition habits (Figure 14 B). In light of these 
results a homogeneous exogenous exposure originating from food consumption can be assumed 
for all the subjects involved in this study. 
 Despite the absence of differences able to discriminate the two groups, an elaboration with 
Auto-CM was performed, in order to evaluate which variables were more strongly associated with 
the disease status or health status. Variables best describing the disease status were: fruit, 
vegetables, white meat consumption and a lower BMI, whereas sweets, bread and croissant 
consumption together with a higher BMI were associated to the control group (Figure 15). 
  
 
 
SU
B
JE
C
T 
ID
 
B
IS
C
U
IT
S 
C
R
O
IS
SA
N
T 
R
U
SK
S 
B
R
EA
D
 
C
R
A
C
KE
R
S 
P
A
ST
A
/ 
R
IC
E 
R
ED
 M
EA
T 
W
H
IT
E 
M
EA
T 
LE
G
U
M
ES
 
P
O
TA
TO
ES
 
FI
SH
 
EG
G
 
C
O
LD
 C
U
TS
 
FR
ES
H
 
C
H
EE
SE
 
R
IP
EN
ED
 
C
H
EE
SE
 
V
EG
ET
A
B
LE
 
FR
U
IT
S 
SW
EE
TS
 
P
IZ
ZA
 
TA
P
 W
A
TE
R
 
B
O
TT
LE
D
 
W
A
TE
R
 
1 SU 1 0 0 1 0 0.67 0.33 0.33 0 0.33 0.33 0.33 0.67 0.33 0.33 1 1 0.33 0.33 Y N 
2 SU 0 0 0.67 1 0 1 0.67 0.67 0.33 0 0.33 0.33 0 0.33 0.33 0.67 1 0.33 0.33 Y N 
3 SU 0 0.33 0 1 0 1 0.33 0.67 0.33 0.67 0.33 0.33 1 1 1 0.67 0.67 1 0.33 Y Y 
4 SU 1 0 1 1 0 1 0 0.67 0.33 0.33 0.33 0.33 0.67 1 0 0.67 1 0.33 0.33 Y N 
5 SU 0.33 0 0 0.67 0.67 0.67 0.33 0.67 0.67 0.67 0.67 0.33 0.33 0.67 0.33 0.67 1 0.67 0.67 N Y 
6 SU 1 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 0 1 N Y 
7 SU 0.33 0 0.33 1 0 1 0.67 0.67 0.33 0.33 0.33 0.67 0.67 1 1 0.67 1 0.67 0.33 Y N 
244 N 0 0 0.33 0.67 0.33 0.67 0.33 0.67 0.33 0 0.33 0.33 0.33 0.33 0.67 1 1 0.33 0 Y N 
245 N 0.67 0 0.67 0.67 0 0.67 0 0.33 0.33 0.33 0.33 0.33 0 0.33 0.33 0.67 0.33 0.67 0.33 Y N 
246 N 0.67 0.67 0.33 1 0 0.67 0.33 0.67 0.67 0.33 0.33 0.33 0.33 0 0.33 0.67 0.67 1 0.67 N Y 
247 N 0 0 0 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 Y Y 
248 N 0.67 0.33 0 1 0 0.67 0.67 0.33 0 0.33 0.33 0 0.33 0.67 0 0.33 0.33 0 0.33 N Y 
Table 4: Food frequency intake as resulted from the survey administered to subjects involved in the study. 0: never, 0.33: once a week, 0.67: two or three times a 
week, 1: every day. SU: ALS patients, N: healthy controls. Y: yes, N: no. 
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Fig. 14. Graphs showing the relations between patients and controls on the basis of food frequency 
consumption. Each node represents a subject (SU= ALS patient; N=healty control). Values on the arches of 
the graph refer to the strength of the association between two adjacent nodes. The range of this value is 
between 0 and 1. A) MST; B) MRG. 
A 
B 
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Fig. 15. Semantic connectivity map obtained with Auto-CM System. The Minimum Spanning Tree (MST) 
shows the connections between the variables obtained with the food frequency questionnaire. Values on the 
arches of the graph refer to the strength of the association between two adjacent nodes. The range of this 
value is between 0 and 1. Red circle identifies variables associated to the ALS group, green circle identifies 
those variables associated to controls. 
  
 Far from being conclusive, these results suggest that a higher BMI and more caloric dietary 
habits seem to be associated to health status with respect to ALS subjects. On the contrary a leaner 
physical shape and “healthier” nutrition habits seem to be associated with ALS. Some authors have 
described already that overweight and obese subjects show a reduced risk to develop ALS (O’Reilly 
et al. 2013), thus increased fat and cholesterol intake may represent a protective factor (Paganoni 
and Wills 2013). Conversely, high levels of physical fitness, thus lower BMI, have been associated to 
a lower survival in ALS (Bouteloup et al. 2009; Huisman et al. 2013). These indications have to be 
considered more as suggestions than conclusions, but results are encouraging further elaboration 
through ANNs. 
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 Furthermore, while pointing out that studies on the quality of public drinking waters and soils 
were not performed in this study and the origin of fruits and vegetables in the subjects' diet was not 
investigated, it should be highlighted that a local origin of these food cannot be excluded. Also, 
locally sourced water could have been likely used for irrigation of crops and gardens and for washing 
fruits and vegetables prior to consumption. As already mentioned, several reviews and meta-
analyses associated pesticides exposure to increased ALS risk (Sutedja et al. 2009; Kamel et al. 2012; 
Malek et al. 2012; Capozzella et al. 2014). Exposure to pesticides has been reported to occur not 
only in professional workers (Bozzoni et al. 2016) and could potentially represent the link between 
fruits and vegetables consumption and ALS, in this small group of subjects. 
 
METALLOMICS 
 
The determination of metal concentrations in serum firstly focused on a panel composed by the 
most relevant metals and trace elements, stemming from the reports of Roos and colleagues (Roos 
et al. 2006 and 2013). The first analysis carried out in our study evaluated concentrations of 
chromium (Cr), iron (Fe), nickel (Ni), copper (Cu), zinc (Zn), arsenic (As), selenium (Se), strontium 
(Sr), cadmium (Cd) and lead (Pb). In a second time, the determination of manganese (Mn), aluminum 
(Al), mercury (Hg), tin (Sn), cobalt (Co), uranium (U), vanadium (V) and barium (Ba) concentrations 
was performed. Most of these elements were reported to be in high concentrations in the mining 
area waters. These determinations took place separately, since the concentrations of the elements 
evaluated in each batch of analyses differ of several order of magnitude, so it would have been 
technically impossible to perform all these analyses together.  Table 5 reports the values of metals 
measured in serum of patients and controls. 
Results show elevated levels of Mn, Al, Ni, Cr, Ba and V both in controls and in patients of 
our study groups in comparison with published reference values for the Italian population (Alimonti 
A, Bocca B, Mattei D 2010). In serum, only the As concentration was significantly different between 
the two groups, with As at lower levels in patients (p < 0.01). Mn levels also were lower in patients 
than in controls, but the difference did not reach statistical significance (p = 0.10). Conversely, Al 
and Se had higher concentrations in patients than in controls but, again, the difference failed to 
reach statistical significance. 
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Element 
Average Patients ± SD 
(μg/L) 
Average Controls ± SD 
(μg/L) 
p-value 
Reference Values 
(µg/L) 
As 0.34 ± 0.03 0.44 ± 0.07 < 0.01 NA 
Mn 1.33 ± 0.69 2.36 ± 1.12a 0.10 0.31-1.02 
Se 100 ± 12 90 ± 8 0.12 56-105 
Al 23.2 ± 5.4 17.2 ± 6.9 0.13 0.4-5.3 
Hg 0.90 ± 0.80 1.62 ± 0.90 0.20 0.32-2.75 
Pb 1.09 ± 0.41 0.83 ± 0.40 0.29 0.20-0.98 
Ni 2.82 ± 0.35 3.00 ± 0.42 0.45 0.26-0.75 
Sn 0.14 ± 0.03 0.17 ± 0.07 0.45 0.27-1.69 
Co 0.49 ± 0.09 0.51 ± 0.03 0.65 0.06-0.42 
Sr 38.4 ± 19.7 34.5 ± 7.2 0.69 23.0-61.5 
U 0.03 ± 0.01 0.02 ± 0.01 0.75 NA 
V 0.96 ± 0.11 0.94 ± 0.12 0.79 0.0-0.11 
Fe 1,165 ± 521 1,225 ± 202 0.81 886-2,455 
Ba 13.26 ± 4.87 12.75 ± 2.14 0.83 0.32-1.37 
Cr 1.56 ± 0.18 1.54 ± 0.08 0.84 0.07-0.28 
Zn 846 ± 151 835 ± 105 0.90 597-1,028 
Cu 1,140 ± 216 1,142 ± 136 0.99 648-1,301 
Table 5. Averages ± Standard Deviation of the measures of metals concentrations in serum. NA: Not 
Available. Reference values from ISTISAN (2010) (Alimonti A, Bocca B, Mattei D 2010). aOne subject from 
controls not analyzed. 
 
AutoCM was able to discriminate the group of patients from the control subjects on the basis 
of the concentration of metals in serum (Figure 16). Low concentrations of As had the strongest 
association with the ALS group. Overall, high concentrations of metals, in particular Se, Al and, with 
a lower closeness, Mn, Sn, Ni, Co and V were linked to the group of patients. Control group was best 
described by high concentrations of As and low concentrations of metals, among which Se and Sr 
were associated with controls more strongly. While analyzing our eating habit questionnaires, we 
also noticed that patients have higher propensity at drinking tap than controls (71% vs 60%). The 
Auto-CM software clusters this variable close to the disease status, with a stronger association with 
serum levels of As and Se. 
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Fig. 16. Semantic connectivity map obtained with Auto-CM System. The Minimum Spanning Tree (MST) 
shows the connections among metals concentrations and water consumption. M: high levels of the metals; 
m: low levels of the metals. Strenght of the connections is always > 0.96. 
 
Possible correlations between metal concentrations in serum and available clinical data were also 
evaluated. Again, the most interesting result regarded As, since its concentration in serum is in 
direct, linear correlation with the duration of disease, calculated as time passed from the onset of 
symptoms to blood sampling or PEG start (Pearson’s ρ = 0,974; p < 0.01 – Spearman’s ρs = 0.857; p 
= 0.01) (Figure 17 A). Furthermore, the increase in serum concentrations of As seems to be time 
dependent, independently of the disease status, and proceeds with the same rate both in patients 
and in controls (Figure 17 B). Se concentration, instead, was inversely correlated with age at onset 
(Pearson’s ρ = -0.804; p = 0.03) (Figure 17 C) and - in a non-linear way - with disease duration 
(Spearman’s ρs = -0.821; p = 0.02) In control subjects, Al (Figure 17 D) and Mn concentrations 
positively correlated with age (R2 = 0.925 and R2 = 0.793 respectively), but no similar correlation was 
detected in patients. 
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Fig. 17 A. Correlation of serum As 
concentration with disease duration 
Fig. 17 B. Correlation of 
serum As concentration with 
age in patients and controls 
Fig. 17 C. Correlation of serum Se 
concentration with age at onset 
Fig. 17 D. Correlation of 
serum Al concentration with 
age in patients and controls 
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The most striking data in our study come from the association of lower levels of As with the 
disease status. This is at contrast with other reports analyzing metals concentration in body fluids 
of ALS patients, where generally an overload was described. In light of this result, was formulated 
the hypothesis that As could be sequestered somewhere and not released in circulation, thus 
altering its clearance.  
The concentration of a smaller panel of metals, among those evaluated in serum, was 
evaluated in whole blood samples, to investigate a possible accumulation of trace element in blood 
cellular components. Table 6 reports the results of concentrations of metals in whole blood. Levels 
of Mn, Zn, Hg, Co and Cr were found higher both in patients and controls in comparison with 
reference values for the Italian population, Pb was higher than reference values only in the patients' 
group, but none of the metals analyzed presented significant differences between patients and 
controls. As and Cr concentrations in the whole blood of patients positively correlated with disease 
duration (for As:  Pearson’s ρ = 0.847; p = 0.02; Spearman’s ρs = 0.750; p = 0.05; for Cr: Pearson’s ρ 
= 0. 800; p = 0.03 - Spearman’s ρs = 0.964; p < 0.01). 
 
Element 
Average Patients ± SD 
(μg/L) 
Average Controls ± SD 
(μg/L) 
p-value 
Reference Values 
(µg/L) 
Co 2.00 ± 0.45 2.39 ± 0.39 0.16 0.03-0.24 
Pb 94.0 ± 46.0 60.6 ± 25.1 0.18 12.8-79.5 
Cr 19.03 ± 4.68 21.56 ± 2.07 0.29 0.12-1.07 
Se 110 ± 18 121 ± 17 0.30 76-140 
Zn 10,134 ± 999 9,492 ± 1,112 0.33 5,189-8,337 
Mn 17.26 ± 3.39 18.54 ± 1.15 0.44 1.53-13.20 
As 8.97 ± 6.90 10.70 ± 4.32 0.65 0.40-11.90 
Hg 17.71 ± 6.81 18.61 ± 3.58 0.79 1.97-14.50 
Cu 1,032 ± 157 1,031 ± 76 0.99 686-1,157 
Table 6. Averages ± Standard Deviation of the measures of metals concentrations in whole blood. Reference 
values from ISTISAN (2010) (Alimonti A, Bocca B, Mattei D 2010). 
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Arsenic concentration, despite being 
lower in patients than in controls, was not 
statistically different. However, As 
concentrations in whole blood and serum 
show a good linear correlation (Figure 18). 
This could lead to the hypothesis that As 
species in serum are in equilibrium with those 
in whole blood. Thus, if an accumulation of 
this element occurs, it should be in an extra-
circulatory district. 
 To evaluate the relationships between blood and serum concentrations of metals, the ratio 
among the values measured in each matrix for each element was calculated. The most interesting 
result was related to Hg (Figure 19). It is evident the low variability in the concentrations’ ratio 
among control subjects, at contrast with what observed for ALS patients.  
The high ratio values are caused by a lower concentration of Hg in serum, whereas 
concentrations in whole blood are similar between patients and controls. This could be interpreted 
as a strong deregulation in the clearance of this element, again supporting the hypothesis of an 
accumulation of this element in an extra-circulatory district. 
The common geographical origin among 
patients and controls allowed to investigate 
metal concentrations in serum and whole blood 
under comparable conditions of environmental 
exposure. A metal overload involving different 
elements was observed both in serum and 
whole blood, possibly reflecting the 
environmental pollution resulting from the 
presence of the mine. The possible influence of 
local sourcing of nutrients is circumstantially 
underscored by the observation that consumption of tap water was associated, through neural 
network analyses, to the ALS group (Figure 16). Although yet inconclusive, this finding calls for an 
in-depth investigation on the levels of metals in water in this area, also in consideration of the use 
of the same water for agricultural and food preparation purposes. Unfortunately, specific and 
Fig. 18. Correlation between serum and whole 
blood As concentrations 
Fig. 19. Blood / serum ratio of Hg concentrations. 
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credible data on water quality in this area and of its content in metals relevant to the present study 
are not available yet. 
The most relevant difference between patients and control subjects is related to As 
concentrations, with As being lower in patient’s serum than in control’s subjects. This result is quite 
surprising, since a pathological condition could be expected to be connected, if anything, to higher 
levels of circulating As. However, As levels strongly correlated with the duration of the disease, 
possibly with connection with the duration of the exposure to the environment. This could support 
the hypothesis of an accumulation of this element over time leading to a damage only in susceptible 
subjects. Serum concentration of As is positively correlated to the concentration of this element in 
whole blood, thus accumulation of As should occur in an extra-circulatory district. In fact, As can 
easily cross the Blood Brain Barrier; furthermore, peripheral neuropathological symptoms are 
common in subjects chronically exposed to As-contaminated drinking water (Vahidnia et al. 2007). 
This point deserves further investigation in this cohort of patients.  
Arsenic can form both inorganic and organic compounds in the environment and in the human 
body, as either arsenite (As3+) or arsenate (As5+). Since absorbed arsenate is mostly reduced to 
arsenite in blood, the effect of the two forms appears to be very similar (Valko et al. 2005). Many 
studies confirmed the generation of free radicals during As metabolism in cells, and oxidative stress 
has been linked to the development of As-related diseases (Shi et al. 2004). On the other hand, As3+ 
induces the transcription of metallothionein-I (MT1) in mouse hepa1c1c7 cells through direct 
interaction with metal-activated transcription factor 1 (MTF1) (He and Ma 2009), and this could 
possibly result in a protective effect, in case of non-toxic levels of As overload.  
The involvement of Se in ALS has been extensively investigated in a well-defined case series of 
residents of the Emilia-Romagna region (Vinceti et al. 2013). These Authors found an association of 
increased ALS risk with higher concentrations of selenite in cerebrospinal fluid (CSF), and of serum 
albumin-bound selenium. We did not investigate Se speciation in our samples, but concentrations 
of total Se were higher in the patient’s group, with the highest values in subjects with the earliest 
onset. 
Considering other neurotoxic elements, Al was found in higher concentration in ALS patients 
than in controls, whereas the opposite was true for Mn. In the control group, concentrations in 
serum of both metals are positively correlated with the age of subjects, possibly reflecting a time-
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dependent non-pathological accumulation. This trend was not identified in the patient’s group, 
maybe due to an alteration in the clearance of these two metal species. 
The role of the analyzed metals in ALS is controversial and these results represent a starting 
point for an in-depth investigation on their possible involvement in the pathogenesis and in the 
course of the disease, as well as in looking for influence of metals with susceptibility disease factors. 
An impaired metal homeostasis could enhance oxidative stress in cells, leading to the production of 
toxic radicals, but can also lead to a redox-dependent competition of suitable metals for the binding 
sites of metal-containing proteins, such as those carrying iron-sulfur clusters and involved in an 
impressive variety of cellular events  (Iametti et al. 1998; Bonomi et al. 1998; De Benedetti et al. 
2016). This damaging effect could be exerted by all those metal species having affinity for thiols, 
whose toxicity in bacteria has been shown to be proportional to the affinity for sulfur (Nies 2003). 
The role of iron-sulfur clusters biosynthetic machinery in ALS is still poorly explored. 
Upregulation of frataxin (Fxn) and of the human orthologue of the cluster-assembly scaffold protein 
(IscU), two of the proteins involved in carrying out or in regulating FeS biosynthesis, has been 
explained as a response of the cell to iron overload (Hadzhieva et al. 2014). However, further 
investigations are required to assess a possible relationship between metal imbalance and the many 
biosynthetic steps leading to functional metalloproteins, as well as the molecular basis of mid- to 
long-term effects of metal imbalance on the energy status and the redox balance of neuronal cells. 
Effects on other proteins involved in metal homeostasis within the cytoplasm or in specific cellular 
compartments (such as metallothioneins or ferritin (He and Ma 2009; Hashimoto et al. 2011; 
Hadzhieva et al. 2013)) and on proteins involved in controlling the intracellular redox potential 
and/or the concentration of active chemical species (such as peroxides and superoxides) also remain 
to be assessed. 
In conclusion, these results suggest that single metal evaluation may underestimate the 
relevance of the role of metals in health risks. It is more likely that all these metals interact with one 
another with an additive or even a synergistic effect (Andrade et al. 2015). If nowadays it is possible 
to analyze simultaneously several trace elements in different tissues, it is still hard to interpret these 
results as a whole. The elaboration of these data with software based on machine learning processes 
and artificial neural networks could be extremely useful to gain a comprehensive view of the 
complex interactions eventually leading to disease. Also, these approaches allow to study 
necessarily small-sized clusters of patients located in a limited geographical area. This combination 
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could be of outstanding value to minimize as much as possible the differences among individuals 
and to investigate further the possible role of environment-related issues in ALS etiology. 
If not for a few studies (Malaspina et al. 2002; Vinceti et al. 2013), other reports on metallomics 
in ALS patients have been performed on wide cohorts of subjects such as US National Registry of 
Veterans (Peters et al. 2016) or cases selected from the Irish ALS register over a time period of 18 
years (Rooney et al. 2016). Although the approaches applied in these studies are extremely valuable 
due to the high number of subjects (allowing to obtain reliable models and statistical analyses), the 
environmental exposure is necessarily highly variable among patients and controls.  
This work is an attempt to switch the approach to these kinds of studies to a better 
consideration of the common environmental exposure. The obvious problematic of the lower 
number of subjects eligible to be involved in these studies could be overcome by using new methods 
of statistical analysis, based on artificial neural networks. At the same time, studies involving a lower 
number of subjects allow deeper evaluations - when the aim is to dissect different aspects 
potentially involved in the disease - of factors that sometimes are impossible to consider together 
in the same cohort of subjects. In light of these considerations, it would be extremely valuable to 
perform such studies after the identification and description of localized clusters of ALS patients, as 
recently reported by Nicoletti et al. (Nicoletti et al. 2016) and previously by Uccelli and colleagues 
(Uccelli et al. 2007). 
 
COMET ASSAY 
 
The comet assay is a rapid and simple technique for the evaluation of DNA damage in all types of 
eukaryotic cells and tissues. This assay has been used in various human biomonitoring studies to 
investigate the effects of exposure to various types of pollutants and environmental contaminants 
(Kassie et al. 2000; Valverde and Rojas 2009).  
Metal compounds have shown to interfere with cellular redox regulation by promoting the 
formation of reactive oxygen species (ROS) and promoting protein and DNA damage. For example, 
chromium is documented to interact directly with DNA, forming Cr-DNA adducts, DNA-protein and 
DNA-DNA crosslinks. Nickel and cadmium showed to inhibit DNA repair enzymes resulting in 
genomic instability and mutations, while arsenic is reported to alter DNA methylation patterns, 
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thereby affecting the expression of oncogenes and tumor suppressor genes (Stohs and Bagchi 1995; 
Beyersmann and Hartwig 2008). Some studies reported increased levels of oxidative damage to DNA 
in sporadic ALS patients (Fitzmaurice et al. 1996; Bogdanov et al. 2000). Others reported a 
correlation between high level of DNA damage and DNA lesions, and high levels of metals (Co, Ni, 
and Pb) in blood and/or urine (Werfel et al. 1998). Some authors hypothesized that the mechanisms 
underlying the genotoxicity produced by these metals are linked to ROS production (De Boeck et al. 
2003; Kasprzak et al. 2003; Botta et al. 2006). Same evidences are reported for Sn (Dantas et al. 
1999; Dantas et al. 2002).  
The analysis of the levels of FPG-sensitive sites - as markers of endogenous DNA damage - 
performed on the whole blood did not show any significant difference between patient and control 
group, since the DNA in tail amounted to 8.3 ± 2.5 % in ALS patients vs 8.2 ± 3.1 % in control subjects 
(p = 0.94) (Table 7). Statistical analyses were performed using Pearson’s and Spearman’s test, and 
only serum Sn concentration positively correlated with endogenous DNA damage in ALS patients 
(Pearson’s ρ = 0.845; p = 0.03) (Figure 20), even though Sn concentrations in serum were lower in 
these subjects than the reference values for the Italian population. No correlation was evident 
between percentage of damaged DNA and clinical parameter such as age at onset and time from 
disease onset. 
Table 7: Results of the comet assay. EB: control sample; FPG: sample treated with FPG enzyme. 
 
In the present study, the levels of endogenous DNA damage did not differ between ALS and 
control group, possibly since both the groups of subjects showed overall comparable levels of metals 
in their blood. Moreover, the levels of DNA damage obtained in the present study were low and in 
line with those generally obtained in our laboratories in apparently healthy subjects or in subjects 
with CVD risk.  
Patients EB FPG % DNA in tail  Controls EB FPG % DNA in tail 
1 SU 37.1 44.4 7.3  244 N 48.5 55.3 6.8 
2 SU 40.8 46.5 5.7  245 N 63.0 67.0 4.0 
3 SU 38.9 46.7 7.8  246 N 65.1 77.4 12.3 
4 SU 50.4 59.2 8.8  247 N 75.4 84.3 8.9 
5 SU 38.2 44.3 6.1  248 N 66.1 74.9 8.8 
6 SU 48.6 61.8 13.2      
7 SU 33.1 42.3 9.2      
  Mean 8.3    Mean 8.2 
  SD 2.5    SD 3.1 
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ALS indeed is a tissue-specific disease, affecting selectively the motor neurons, and the 
relevant oxidative insults, possibly responsible for the disease, are only those – if any – involving 
motor neurons. Comet assay performed at low doses of H2O2 in NSC34 cells, a line of immortalized 
motor neuronal cells, revealed that overexpression of either wild type SOD1 and G93A-SOD1 mutant 
resulted in protection from free radical damage in nuclei (Sau et al. 2007). However, results reported 
in this study, were obtained in PBMCs. Hence, the evidence is not conclusive about the connection 
between ALS and DNA oxidative stress. Indeed, a recent work reports that an altered intracellular 
localization of SOD1 in leukocytes from patients with SALS (Cereda et al. 2013), could lead to a higher 
peripheral protection in subjects affected by the disease, with effective contrast of the oxidative 
DNA damage down to physiological levels. 
Fig 20: Correlation of Sn serum concentration with % of DNA damage in ALS patients. 
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PROTEOMICS 
 
2DE analyses of the serum proteome in both controls and patients have been carried out under 
reducing as well as under non-reducing conditions. Table 8 lists the results for those proteins in 
which a significant difference in volume was observed under reducing conditions in one or more of 
their spots, corresponding to one or more of their PTM-species (Jungblut et al. 2008) or of their 
proteolytic fragments, in a patients vs controls comparison.  
Lower levels of apolipoprotein A-I (APOA1), apolipoprotein A-II (APOA2) and transthyretin 
(TTR) were found in patients, whereas antithrombin-III (SERPINC1) was markedly increased. To 
highlight features associated with early vs late onset the comparison was then shifted to two 
subgroups in which patients were sorted depending on whether the onset of the disease had 
occurred before or after their being 60 years in age. With respect to controls, lower amounts of 
retinol-binding protein 4 was found in patients with an earlier (and more remote) onset, but not in 
patients with a late (and more recent) onset. Figure 21 presents 2DE maps obtained under reducing 
conditions, that allowed the identification of these proteins. 
Protein Gene name 
Uniprot 
accession # 
All 
Patients 
Onset ≤ 60 
years (n = 4) 
Onset > 60 
Years (n = 3) 
apolipoprotein A-I APOA1 P02647 -17 % * = -22 % ** 
transthyretin TTR P02766 -30 % * -28 % ** -32 % ** 
antithrombin-III SERPINC1 P01008 +71 % * +71 % ** = 
retinol-binding protein 4 RBP4 P02753 = -25 % ** = 
apolipoprotein A-II APOA2 P02652 -30 % * -29 % ** -33 % ** 
Table 8. Differential abundance, % variation between controls and patients, of the serum proteome 
components evaluated with 2DE under reducing conditions and identified by MS. *p ≤0.05, **p ≤ 0.1  
 
In figure 22 is reported one representative gel among those performed in non-reducing conditions. 
This separation condition allowed the identification of several additional spots with a significantly 
different mean volume between patients and controls. In one case, these corresponded to species 
or fragments of a protein already identified, but others proteins were only evident under these 
conditions, as summarized in Table 9. 
 
 
 
Fig. 21. Representative 2DE gel performed under reducing conditions 
 
 
 
Fig. 22: Representative 2DE gel performed under non-reducing conditions
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Protein Id 
Uniprot 
accession # 
Patients Controls P-value 
% variation in 
patients vs 
controls 
apolipoprotein A-I 18_fAPOA1 P02647 0.07 ± 0.02 0.10 ± 0.02 0.06 -30% 
apolipoprotein A-I 21_fAPOA1 P02647 0.06 ± 0.02 0.14 ± 0.06 0.02 -57% 
apolipoprotein A-I 22_fAPOA1 P02647 0.12 ± 0.05 0.21 ± 0.06 0.03 -42% 
apolipoprotein A-IV 6_APOA4 P06727 0.13 ± 0.05 0.19 ± 0.06 0.09 -31% 
apolipoprotein A-IV 12_fAPOA4 P06727 0.08 ± 0.02 0.23 ± 0.06 < 0.001 -65% 
protein AMBP 15_AMBP P02760 0.08 ± 0.05 0.05 ± 0.01 0.02 +60% 
clusterin 4_CLUS P10909 0.45 ± 0.25 0 < 0.001 - 
clusterin SUM_CLUS P10909 1.94 ± 0.74 1.22 ± 0.37 0.09 +60% 
Table 9. Differential abundance between controls and patients of the serum proteome components 
evaluated with 2DE under non-reducing conditions and identified by MS. Relative abundances are expressed 
as % vol ± SD. Id: spot tag; SUM_CLUS: sum of the values relative to all clusterin species 
 
The abundance of some proteins, calculated as the sum of the intensities of all the individual spots 
identified by MS was correlated with the duration of the disease (i.e., years from the time of onset 
to the time of blood sampling or PEG start). A positive correlation is present between disease 
duration and protein levels for alpha 1-acid glycoprotein (Pearson’s ρ = 0.791, p = 0.03; Spearman’s 
ρs = 0.857, p = 0.01) and leucine-rich alpha-2-glycoprotein (Spearman’s ρs = 0.750, p = 0.05). 
Conversely, a negative correlation was found for apolipoprotein A-II (Pearson’s ρ = -0.718, p = 0.07; 
Spearman’s ρs =- 0.893, p = 0.007) and transthyretin (Pearson’s ρ = -0.866, p = 0.01; Spearman’s ρs 
=- 0.893, p = 0.007) as shown in figure 23. From these graphics is evident that any variation is non-
linear, regardless of whether a given protein is increasing or decreasing. The most drastic evolution 
of the abundance of the proteins occurs in the early years of the disease, while in the long-lasting 
subjects the variation is less pronounced. 
 
 
 
Fig. 23.  Correlations of proteins relative abundance with disease duration. Non-linear trend is shown by the regression dotted line.
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A dataset composed by the proteins found in different abundance through the 2DE 
approaches (APOA1, TTR, SERPINC1, RBP4, APOA2, APOA4, AMBP, CLUS, LRG1 and ORM1) was used 
as a query in the String Database (ver. 10.0), a database able to reconstruct known and predicted 
protein-protein interactions. The interactions include direct (physical) and indirect (functional) 
associations, assessed on the basis of computational prediction, knowledge transfer between 
organisms and interactions aggregated from other (primary) databases (Szklarczyk et al. 2015). In 
the output graph, nodes represent the proteins of interest, among which are obviously present 
those input by the user, their closest interactors (represented as colored balloons) and the 
secondary interactors (white balloons). Edges instead, represent specific and meaningful protein 
associations, that do not necessarily involve a physical binding between proteins, but rather reflect 
their contribution to a shared function. These interactions are derived from experimental evidences 
and curated databases, but can also be predicted from gene neighborhood, gene fusions and gene 
co-occurrence.  
Other interactions can be assessed from text-mining, and from co-expression and protein 
homology data. All the proteins found in differential abundance in the 2DE experiments are highly 
interconnected, as shown in Figure 24. From this analysis is possible to define a cluster of proteins 
involved in lipid homeostasis (red circle), one involved in coagulation cascade (blue circle) and one 
involved in cellular apoptosis and DNA repair (yellow circle). 
Most of these proteins are involved also in Acute Phase Response. Gene Ontology and KEGG 
Pathway analysis assessed an enrichment in proteins whose molecular function is related to 
cholesterol and lipid metabolism (Table 10). As highlighted by KEGG analysis there are also present 
proteins, strictly interacting with the entries, that are involved in neurodegeneration in general and 
ALS specificlly (APOE, PSEN1, BAX, BCL2 and BID). These results highlight the necessity to consider 
the proteins selected from 2DE analyses as a part of a complex network, as their differential 
abundance may be the reflection of a broad array of biological interactions. In the same time, this 
approach could be useful to identify other interactors potentially involved in ALS, not yet 
considered. 
 
 
 
 
 
 
Fig. 24. Output network from STRING analyses. Detailed description is reported in the text. (http://string-
db.org/). 
 
  
 
 
Molecular Function 
(Gene Ontology) 
Observed 
gene count 
FDR Network matching proteins 
cholesterol 
transporter activity 
7 2.92E-12 ABCA1, APOA1, APOA2, APOA4, APOB, APOE, CETP 
cholesterol binding 7 1.04E-09 ABCA1, APOA1, APOA2, APOA4, APOC3, APOE, CETP 
protein binding 29 2.93E-09 
ABCA1, AMBP, APBB1, APOA1, APOA2, APOA4, APOB, APOC3, 
APOE, APP, BAX, BCL2, BID, CLU, F2, FGB, HNF4A, LCAT, LRP2, PLG, 
PRKDC, PSEN1, SERPINC1, TGFB1, TGFBR1, TGFBR2, TTR, XRCC5, 
XRCC6 
lipid transporter 
activity 
8 3.30E-09 ABCA1, APOA1, APOA2, APOA4, APOB, APOE, CETP, RBP4 
alcohol binding 8 4.11E-09 ABCA1, APOA1, APOA2, APOA4, APOC3, APOE, CETP, RBP4 
phosphatidylcholine-
sterol O-
acyltransferase 
activator activity 
4 8.98E-08 APOA1, APOA2, APOA4, APOE 
lipoprotein particle 
receptor binding 
5 1.38E-07 APOA1, APOA2, APOB, APOC3, APOE 
lipid binding 12 3.20E-07 
ABCA1, APOA1, APOA2, APOA4, APOB, APOC3, APOE, BAX, CETP, 
F10, HNF4A, RBP4 
receptor binding 14 1.58E-06 
ABCA1, APOA1, APOA2, APOB, APOC3, APOE, APP, BID, F2, HNF4A, 
PLG, TGFB1, TGFBR1, TGFBR2 
high-density 
lipoprotein particle 
receptor binding 
3 2.19E-06 APOA1, APOA2, APOC3 
phospholipid binding 9 2.63E-06 ABCA1, APOA1, APOA2, APOA4, APOB, APOC3, APOE, CETP, F10 
KEGG pathway 
description 
Observed 
gene count 
FDR Network matching proteins 
Complement and 
coagulation cascades 
9 2.07E-12 F10, F2, F5, F9, FGA, FGB, PLG, PROC, SERPINC1 
Fat digestion and 
absorption 
4 0.000141 ABCA1, APOA1, APOA4, APOB 
Non-homologous end-
joining 
3 0.000187 PRKDC, XRCC5, XRCC6 
Colorectal cancer 4 0.00033 BAX, BCL2, TGFB1, TGFBR2 
Alzheimer s disease 5 0.000781 APBB1, APOE, APP, BID, PSEN1 
Vitamin digestion and 
absorption 
3 0.000781 APOA1, APOA4, APOB 
Amyotrophic lateral 
sclerosis (ALS) 
3 0.00522 BAX, BCL2, BID 
Non-alcoholic fatty 
liver disease (NAFLD) 
4 0.00686 BAX, BCL2L11, BID, TGFB1 
Tuberculosis 4 0.00956 BAX, BCL2, BID, TGFB1 
PPAR signaling 
pathway 
3 0.00956 APOA1, APOA2, APOC3 
Pathways in cancer 5 0.00995 BAX, BCL2, BID, TGFB1, TGFBR2 
Apoptosis 3 0.0141 BAX, BCL2, BID 
Neurotrophin 
signaling pathway 
3 0.0324 BAX, BCL2, PSEN1 
FoxO signaling 
pathway 
3 0.034 BCL2L11, TGFB1, TGFBR2 
Hepatitis B 3 0.0483 BAX, BCL2, TGFB1 
Table 10. Molecular function description and pathways in which proteins submitted to the software and 
their interactors are involved. FDR: False Discovery Rate. 
 
 
All the results obtained from 2DE performed in non-reducing conditions were then analyzed with 
AutoCM software (Semeion 2009-2012 ver 8.0). Use of non-reducing condition was preferred, since 
it allowed the identification of a higher number of proteins. The software was able to group all the 
species and/or fragments identified for each protein by relying only on the relative intensity of 
individual spots. Using the % volume data, AutoCM was able to discriminate the group of ALS 
patients from the group of healthy controls (Figure 25). 
Fig. 25. Semantic connectivity map obtained with Auto-CM System. The Minimum Spanning Tree (MST) 
shows the connections between species and/or fragments of the peptides selected with MS. Values on the 
arches are > 0.96 for all the connections. These refer to the strength of the association between two 
adjacent nodes. The range of this value is between 0 and 1. 
 
The closest nodes, i.e. those most strongly associated to ALS, correspond to low levels of various 
fragments of apolipoprotein A-I and A-IV, and to high levels of protein AMBP, zinc-alpha-2-
glycoprotein and one clusterin species, that was found only in six out of seven patients, but never 
in controls. Nodes featuring a looser association, but still clustering in the ALS group, correspond to 
low levels of apolipoprotein A-II, apolipoprotein C-II and C-III, retinol-binding protein 4, and 
transthyretin, in agreement with results obtained from 2DE performed in reducing conditions. High 
 
 
levels of alpha-1-acid glycoprotein 1 and of the other clusterin species are also associated with the 
ALS group. 
A confirm of the potential of this approach is attributable to the ability of the software to put in 
close association the different fragments or species of the same protein, as particularly evident in 
the case of clusterin, where the train of species detected in the gel is almost perfectly reproduced 
by the software, especially in the healthy subject group. The same can be stated for the transthyretin 
fragments, all closely associated each other. Furthermore, the most strongly associated protein to 
the transthyretin group is retinol binding protein 4, that in bloodstream, interacts with transthyretin 
itself, preventing its loss by filtration through the kidney glomeruli. 
All proteins for which a significantly different abundance in ALS patients vs controls was 
observed are involved in the Acute Phase Response (APR), a systemic reaction to a wide variety of 
stimuli able to cause tissue damage. Indeed, the differential abundance detected for several 
components of the serum proteome could be related to the compromised general status of the 
patients. During APR, a massive alteration occurs in the concentration of plasma/serum proteins, 
some of them resulting in increased and some other in decreased circulating levels. Indeed, all the 
proteins found in lower concentration in ALS patients than in controls are known as negative acute 
phase reactants. An alteration in APR proteins in ALS patients was described in a recently published 
proteomic study performed on Cerebrospinal Fluid (CSF) (Chen et al. 2016).  
Some of the proteins identified in this study are involved in lipid homeostasis, and neural 
network analysis associated low levels of APOA1, APOA2, APOA4, APOC2 and APOC3 with the ALS 
group. This is consistent with a proposed metabolic shift towards an increased peripheral use of 
lipids in ALS (Fergani et al. 2007) and with the evidence of hypolipidemia in presymptomatic murine 
ALS models (Kim et al. 2011). Another study, where ANNs were applied to unravel the hidden 
connections between the variables on sporadic ALS, highlighted that Single Nucleotide 
Polymorphisms (SNPs) in genes involved in lipid pathways were associated to the disease, among 
which APOA4 was present (Buscema et al. 2012). 
Many of the spots found differentially expressed correspond to APOA1 degradation products 
(proteolytic fragments). Apolipoprotein I is degraded in vivo mainly by Matrix Metalloproteases 
(MMPs) whose activation is driven by the oxidation of the conserved cysteine in the propeptide 
sequence (Van Wart and Birkedal-Hansen 1990; Eberini et al. 2007). Evaluation of the influence of 
metals on MMPs activity (including the possible replacement of the original metal cofactor with 
 
 
other species) could be an interesting follow up of this work, in light of the hypothesis discussed 
above of a potential heavy metals pollution to soil and water.  
Enzymes like plasmin, thrombin, and kallikrein, involved in the coagulation/fibrinolytic 
pathway, are able to degrade APOA1 to similar proteolytic fragments (Kunitake et al. 1990). One of 
their specific plasma inhibitor, antithrombin III, as well as another protease inhibitor (protein 
AMBP), are present at higher concentration in ALS subjects, particularly in those with disease onset 
before 60 years of age. This could be a likely explanation for the low abundance of APOA1 
proteolytic fragments observed here. 
Conversely, levels of clusterin were higher in serum samples from patients than from controls. In 
bloodstream clusterin is a component of the lipid-poor subclass of lipoproteins, the high density 
lipoproteins (HDL), which also contain APOA1 and paraoxonase (Jenne et al. 1991). Clusterin acts as 
a molecular chaperone, but it is also involved in apoptosis and, of course, in lipid transport (Koltai 
2014), thus providing an interesting connection between lipid and protein homeostasis. Unfolded 
Protein Response (UPR) is triggered in ALS pathology, leading to the induction of chaperones to 
increase protein folding/refolding capacity (Kanekura et al. 2009). Furthermore, high levels of 
clusterin have been associated to cognitive decline in Alzheimer’s Disease (AD). Specifically, a Single 
Nucleotide Polymorphism (SNP) within the clusterin gene has been described as a risk factor for AD 
in two independent genome-wide association studies (Harold et al. 2009; Lambert et al. 2009), thus 
providing a link to neurodegeneration. In a study on healthy Korean adults, Won et al. (2014) 
proposed that circulating levels of clusterin might be related to the pro-inflammatory state 
associated with increasing adiposity, and that it could represent a potential biomarker of 
inflammation-related human disease(s). Interestingly, in this study, higher levels of clusterin and 
lower levels of apolipoprotein A-I were detected, even though in the bloodstream they are 
associated within the supramolecular assembly of HDL particles, calling for further and deeper 
characterization. Finally, a link with the metals analyses previously reported is provided by a study 
stating that selenium-enriched yeast administration to healthy subjects, leads to increased 
circulating levels of serum clusterin isoform 1 (Sinha et al. 2010). In the metals analyses described 
previously a higher concentration of selenium was associated with the ALS group. On this basis, it 
seems worth evaluating further the link between metals concentration and serum proteins in ALS. 
Another protein associated at high levels to the ALS group by the Auto-CM software is zinc-
alpha-2-glycoprotein (ZA2G). Increased concentrations of this protein have already been described 
in ALS after a proteomic analysis on CSF (Brettschneider et al. 2008). Interestingly, ZA2G was also 
 
 
reported to be affected in the CSF proteome of patients with frontotemporal dementia (FTD), a 
pathology that overlaps with ALS in some patients (Hansson et al. 2004). The function of this protein 
is related to the stimulation of lipolysis and the reduction of body fats (Vanni et al. 2009), which 
circumstantially support the involvement of proteins related to lipid homeostasis. 
ALS biomarkers are badly needed to help diagnosis, to monitor the progression of the disease, 
and to define suitable endpoints for clinical trials. Concentration of alpha 1-acid glycoprotein or 
oromucoid (ORM1) and of leucine-rich alpha-2-glycoprotein (LRG1), while not significantly differs 
overall between patients and controls, steadily increases during the progression of the disease, and 
higher concentrations have been measured in patients with a longer disease course than in those 
with a shorter one. ORM1 is one of the major acute phase proteins in humans (Fournier et al. 2000) 
and it turned out to be one of the four circulating biomarkers able to predict the risk of all-cause 
mortality, in a study performed on participants from Estonian Biobank (Fischer et al. 2014). LRG1 is 
involved in protein-protein interaction, signal transduction, and cell adhesion and development 
(O’Donnell et al. 2002). 
Despite not being conclusive, our data advocate focusing future investigation on the evolution 
of the concentration of these proteins with time. Apolipoprotein A-II and transthyretin, on the 
contrary, keep decreasing during the course of the disease. In view of the opposite trends, the 
evolution of a panel of such biomarkers and of their combinations could turn out to be especially 
effective in monitoring the disease. 
In conclusion, 2DE technology still reveals its potential in proteomic studies. It is nowadays a 
well-known and very valuable approach to assure resolution and pattern recognition in complex 
matrices. Furthermore, it provides a very wide spectrum of customizable solutions, with minimal 
changes in the work pipeline, according to user requirements. 
The culprit of proteomic studies is often data managing and interpretation of results. This 
study also reveals that data mining through software based on ANN appears very promising in 
dissecting the complexity of a multifactorial disorder such as ALS. Specifically, this approach may 
help to unravel the hidden interactions among variables that would be almost impossible to analyze 
with conventional statistical methods. Furthermore, this approach evolved specifically to manage 
situations where subjects are very low in number and several variables are at work, as is the case 
here, but, more in general, as is the case of the study of rare diseases. It is reassuring that most of 
the results obtained in this study confirm, or are in general agreement, with literature evidences 
 
 
obtained with different approaches and on much larger cohorts of ALS patients; analyzing well 
defined cohorts of human patients, despite presenting the problem of a low number of subjects, 
could be a reliable model to study ALS. This approach would allow to evaluate different aspects of 
the disease all together, in order to have a more comprehensive view of the disease in the same 
group of subjects. 
After extensive literature research, this appears to be the first report of serum proteome in 
subjects affected by sporadic ALS, obtained with 2DE. Despite its complexity, serum is the most 
accessible biological tissue, both in clinical practice and for basic research. The search for multiple 
biomarkers to help physicians in diagnosis would lead to a better care of patients; along with this 
practical implication, this would also provide useful insights into disease mechanisms. Indeed, at 
present, the leading field in ALS research is based on genomic studies. However, this approach is 
limited because genetics explains only a small percentage of ALS cases, and among these cases, very 
rarely a specific mutation is able to provide information on the onset and the course of disease, 
given the complex interactions that are supposed to drive the evolution of ALS. Evaluating the 
protein expression, that is the result of genetic background and post-transcriptional and post-
translational events, together with protein transport, secretion and degradation, would be the key 
to discover their role in pathological conditions. 
Most of the studies performed up to now, that led to define geographical clusters of ALS, were 
limited to describing this phenomenon only from the epidemiological point of view (Veiga-Cabo et 
al. 1997; Uccelli et al. 2007; Sabel et al. 2009; Alonso et al. 2011; Boumédiène et al. 2011; Keren et 
al. 2014; Henry et al. 2015). The study of geographical clusters, such as those found in Guam or Kii 
Peninsula, has been successful in the past years, to get more insights into the pathology of ALS. Basic 
research performed on ALS patients originating from a small geographical area, as described here, 
has the potential to be valuable for a systematic evaluation of various aspects of the disease, 
integrating different methods of analysis, in subjects with a common environmental background. 
  
 
 
GENETICS 
 
A screening for the most frequently mutated genes in ALS was performed in order to assess if the 
higher prevalence of ALS, detected in the study area, could be attributable to a genetic mutation, 
since it is often the cause for the appearance of a disease cluster, within a family or a geographical 
area. 
 As generally approved in clinical practice, the genetic test was performed overall SOD1 gene, 
on exon 6 of TARDBP gene and on exons 5, 6, 13, 14 and 15 of FUS gene, the latter, considered 
mutational hotspots. Exons and intron-exon boundaries were PCR amplified and sequenced. None 
of the sequenced genes revealed mutations nor SNPs. As detailed under Methods, the presence of 
a C9orf72 hexanucleotide expansion was evaluated, but results were negative for all ALS patients. 
Even if the influence of genetic factors in the determination of this cluster of patients cannot be 
totally excluded - given the always possible presence of rare variants - the absence of alterations in 
the most frequently mutated genes and the absence of a positive family history for 
neurodegenerative diseases led us to focus on other factors potentially involved in the disease. 
As most proteomic findings point to an altered lipid metabolism, APOE genotype was 
evaluated in subjects involved in the study. Literature data indicate Apolipoprotein E (ApoE) as a 
link between lipids homeostasis and neurodegeneration, in particular in Alzheimer disease (AD) and 
- more controversially - in ALS. Furthermore, the evidence of an association of ApoE with 
differentially abundant proteins detected through proteomic studies, emerged also from the 
STRING analysis of the results described above. ApoE comprises a class of apolipoproteins essential 
for the normal catabolism of triglyceride-rich lipoprotein constituents. On the basis of the 
combination of polymorphisms in two positions, it may exist in three isoforms: ApoE2 (Cys112, 
Cys158), ApoE3 (Cys112, Arg158), and ApoE4 (Arg112, Arg158) (Ghebranious et al. 2005). The 
APOE*3 allele is the most common and does not seem to influence the risk of developing AD; the 
APOE*2 allele appears to lower it, whereas the APOE*4 allele has been associated to an increased 
risk for AD and other neurodegenerative conditions such as ALS (Corder et al. 1993; Praline et al. 
2011). 
 
 
Table 11 compares genotypes and allelic frequencies of APOE in the group of patients, in the healthy 
controls and in the whole population of Caucasian ancestry, as reported in the Alzheimer Research 
Forum website (http://www.alzgene.org/meta.asp?geneID=83).  
Population 
Allele Genotype 
2 3 4 2/2 2/3 3/3 2/4 3/4 4/4 
Caucasian 0.08 0.78 0.14 0.01 0.12 0.61 0.02 0.22 0.02 
Controls 0.10 0.80 0.10 0.00 0.20 0.60 0.00 0.20 0.00 
ALS 0.00 0.71 0.29 0.00 0.00 0.43 0.00 0.57 0.00 
Table 11. Frequencies of ApoE alleles and genotypes in the study populations and in the general Caucasian 
population 
 
Despite the low number of control subjects, the results obtained from the cohort analyzed are 
concordant with literature data about the frequency of the alleles and of the genotypes in the 
healthy Caucasian population. Conversely, the allelic frequency for the APOE*4 allele is 3-fold higher 
as well as APOE*3/APOE*4 genotype in the patients’ group than in control’s. This finding leads to 
hypothesize that the APOE*4 allele might act as a genetic susceptibility factor or disease modifier 
in this group of SALS patients. However, the low number of subjects considered in this study must 
always be considered as a limit when raising such hypotheses.  
Another disease associated factor, linking lipid metabolism and protection from 
environmental stressors, is represented by the paraoxonase gene cluster, localized on chromosome 
7q21.3 and containing PON1 and PON2 genes. The PON1 protein is secreted by the liver, is 
associated with high-density lipoproteins, (HDL) and it prevents peroxidation of LDL through its 
antioxidant capacity. It is also able to detoxify organophosphate insecticides, pesticides and nerve 
gases (Li et al. 2003). PON2 is an intracellular protein, ubiquitously expressed with the function to 
protect cells from oxidative damage. Cells overexpressing PON2 are less prone to oxidize LDL and 
show considerably less intracellular oxidative stress when exposed to either H2O2 or oxidized 
phospholipid (Ng et al. 2001).  
Single Nucleotide Polymorphisms (SNPs) have been identified in these genes as associated to 
the enzyme activity, plasma concentrations and lipoprotein metabolism. In detail, PON1 activity in 
paraoxon and chlorpyrifos oxon hydrolysis is reported to be enhanced by a Glutamine (Q) to 
 
 
Arginine (R) substitution in position 192 (rs662), while the presence of a methionine (M) instead of 
a leucine (L) in position 55 (rs854560) is thought to be associated to lower serum concentration of 
this enzyme and to higher protective capacity towards LDL oxidation (Humbert et al. 1993; 
Zafiropoulos et al. 2010). The substitution of a Serine (S) to a Cysteine (C) in position 311 in PON2 
(rs6954345) has been associated to variations in its plasmatic concentrations and to lipoproteins 
metabolism (Li et al. 2003). Homozygous subjects for the Serine substitution at position 311 have 
significantly higher APOB concentration, total plasma, and LDL cholesterol, conversely they have the 
lowest amount of HDL and APOA1, than subjects with the other two genotypes (Boright et al. 1998). 
Table 12 reports allele and genotype frequencies of the analyzed SNPs in patients and healthy 
controls and compares them to the frequencies detected in the European population in the 1000 
Genomes Project (Auton et al. 2015). Allelic frequencies in control group do not differ from those 
reported for the European population, except for PON2 S311C, where a higher frequency of the 
serine-containing isoform was detected in the control group. 
Table 12. Frequencies of PON alleles and genotypes in the study populations and in the European population  
 
When comparing ALS and control group from the study population, PON1 Q192R genotype and 
allelic distribution were present in the same proportion. Genotype frequencies relative to PON1 
L55M polymorphism reveal an almost 3-fold higher frequency of the homozygous MM, while no 
heterozygous subjects were detected in controls. Regarding PON2 S311C allelic frequencies, the 
cysteine isoform was two times more frequently detected in ALS patients, the same for the 
heterozygous state. The low number of subjects in this analysis made impossible the application of 
statistical tests in order to evaluate if differences are significant. However, the higher frequency of 
Population 
PON1 L55M PON1 Q192R PON2 S311C 
Allele Genotype Allele Genotype Allele Genotype 
L M LL LM MM Q R QQ QR RR S C SS SC CC 
ALS 0.71 0.29 0.57 0.29 0.14 0.79 0.21 0.57 0.43 0 0.79 0.21 0.57 0.43 0 
Controls 0.60 0.40 0.60 0 0.40 0.80 0.20 0.60 0.40 0 0.90 0.10 0.80 0.20 0 
EUR 
(Chr=1006) 
0.64 0.36    0.71 0.29    0.75 0.25    
 
 
the homozygous PON2 S311C in controls, could be associated to a protecting effect, supported by 
the fact that this genotype is associated to hyperlipidemia, reported, as already discussed, to be 
protective towards ALS. A similar effect could be hypothesized, in this cohort of subjects, also thanks 
to the finding of an apparently higher frequency of PON1 M55M genotype, associated to a higher 
protection from LDL oxidation. 
Several studies tried to establish an association of PON cluster with SALS, but previous meta-
analyses failed to detect any association between the analyzed SNPs and the disease (Wills et al. 
2009). Data reported here are consistent with these findings, so that it still remains difficult to 
ascertain if PON genes could have a role in the disease. As different mutations in PON genes have 
been reported in ALS patients, their involvement cannot be excluded, with a pathogenic mechanism 
likely to reflect some properties shared by mutant PON proteins (Ticozzi et al. 2010). Further support 
to PON involvement in ALS is provided by their own role in protection from oxidation. In ALS indeed, 
motor neurons are exposed to abnormal levels of oxidative stresses such as lipid peroxidation in a 
chronic condition (Shibata et al. 2001). PON1 indeed, may have a role in protecting cellular 
membranes facing these conditions of exposure to oxidative agents and free radicals (Rodrigo et al. 
2001). 
Considering these data, the study performed in this cohort of patients, thus not providing 
evidences in the involvement of PON polymorphisms in ALS, provides some connections valuable to 
be considered. First, the alterations in lipid transport proteins detected with 2DE may alter the 
assembly of the supramolecular complexes, in which PON1 is involved. Changes in HDL size and 
shape are able to strongly affect the binding affinity and stability of PON1 resulting in impaired 
antioxidative capacity (Durrington et al. 2001). A specific PON genotype can affect the lipid 
metabolism through some still unknown mechanisms and, vice versa, lipid homeostasis alterations 
may have different detrimental effects on the organism because of a given PON genotype. 
Secondly, it is reported that some elements, such as barium, lanthanum, copper, zinc, and 
mercurials are able to inhibit PON1 activity in rat or human liver (Gonzalvo et al. 1997). In the light 
of the high levels of metals reported in the area of this study, it would be interesting in the future, 
to evaluate the activity of PON enzymes and to correlate it with levels of metals detected in subjects 
involved in the study. 
Lastly, in literature PON2 S311C and APOE*4 polymorphisms are described to have interactive 
effects on the development of AD related dementia (Janka et al. 2002). ApoE and PON1 L55M 
 
 
polymorphisms show relevant interactions in establishing the risk for Coronary Artery Disease, 
demonstrating effectively functional interaction (Murphy et al. 2002), that may be relevant also in 
ALS. 
 
NUTRITIONAL INTERVENTIONS IN ALS 
 
The lack of an effective pharmacological treatment and the long time and costs required for the 
testing of safety and efficacy of new drugs (comprising stem cells and gene therapy), led researchers 
and patients itself to look for alternative ways to manage the disease. Nutritional interventions are 
actually in use with the aim of replacing normal feeding since it becomes impossible with the 
progression of the disease. 
In the light of the results reported in this study, with the support of literature data, an 
approach pointed to modulate lipid homeostasis and/or manage metals impairment, through a 
properly designed nutritional intervention, could be a low-cost and non-pharmacological promising 
way to manage the disease in the short time. 
Enteral nutrition by percutaneous endoscopic gastrostomy (PEG) or radiologically inserted 
gastrostomy (RIG) is generally recommended once patients have lost 10% of their premorbid weight 
(Greenwood 2013). For patients who need to be fed via a gastrostomy tube, no nutritional 
guidelines or consensus regarding recommendations for enteral nutrition are available. Dietary 
supplements are frequently used, but this intervention is usually based on anecdotal evidences in 
the hope of potential efficacy, in the absence of evidence-based research (Braun and Osecheck 
2012). 
Malnutrition is a common feature and is an independent negative prognostic factor for 
survival in ALS due to the deterioration of functional disabilities such as difficulties in mastication, 
oral transit and dysphagia. Furthermore, ALS patients, despite the progression of the disease leads 
to paralysis, experience a paradoxical abnormal increase in energy expenditure (hypermetabolism). 
Consequences of an inadequate dietary intake lead to the exacerbation of catabolism, muscle 
atrophy and weakness of the immune system (Cameron and Rosenfeld 2002). In consequence, 
appropriate nutritional intake seems to have the potential to modify the development of the 
disease. 
 
 
Findings of the study here presented point to an alteration in the lipid profile in ALS patients, 
which is consistent with literature data. In fact, experiments performed on SOD1 transgenic mice 
show that mutant strains have a lower BMI than littermates, due to impaired lipid storage in white 
adipose tissue (Dupuis et al. 2004). Low lipid storage can be found before the animals develop motor 
signs and appears to be related to elevated energetic demand with recruitment of lipid body stores. 
When fed with a rich fat diet animals lived longer than those fed with normal diet (Hamadeh et al. 
2005).  
Resting energy expenditure (REE) is reported to be increased during the disease and leads to 
the depletion of energy stores, in particular, lipid reserves. Thus, hyperlipidemia and high BMI have 
been proposed as factors potentially able to modulate survival in ALS (Dupuis et al. 2008; Paganoni 
et al. 2011). Furthermore, cholesterol and phospholipids, in particular low-density lipoproteins, are 
essential to maintain a healthy axonal membrane and for peripheral nerve membrane injury repair 
(Posse de Chaves et al. 1997). 
Considering these results, supported by data presented in this work, some clinical trials are 
currently being performed to evaluate the impact of nutritional intervention in ALS. At present an 
ongoing trial (NCT02152449) is aimed at evaluating the efficacy of a systematical and early oral 
nutritional supplementation, in order to allow patients to maintain proper nutritional status, and its 
impact on neurological functions. Such an intervention could delay the progression of the disease if 
the metabolic disorders in ALS are not only the result of progression of the disease, but are 
implicated in its course and outcome. 
Another study, based on a dietary intervention, aimed at evaluating tolerability and safety 
of increasing bodyweight in ALS patients already receiving PEG and evaluated if it could improve 
survival (NCT00983983). Patients were split in three study arms: calorie replacement using an 
isocaloric diet with a goal of weight stability (control), a high-carbohydrate hypercaloric diet (HC/HC) 
and a hypercaloric diet high in fat calories (HF/HC). Hypercaloric diets were aimed at increasing body 
weight by giving about 125% of estimated energy requirements for 4 months. The study 
intervention resulted safe and tolerable since patients who received a HC/HC tube-feeding formula 
were less likely to have serious adverse events, including death, during the 5-month follow-up than 
were controls. The study results supported hypercaloric enteral nutrition as a new and potentially 
robust nonpharmacological intervention in ALS (Wills et al. 2014). 
The mentioned study was not able to demonstrate that a hypercaloric diet high in fat calories 
could provide benefits in ALS patients, but it resulted instead in weight loss. Authors propose that 
 
 
it could be related to the higher rates of gastrointestinal side-effects compared with the HC/HC diet 
even if previous studies using this feeding formula had not reported weight loss as a side-effect 
(Wills et al. 2014). 
Several evidences point to a potentially beneficial effect of a high fat diet in managing ALS. 
First of all, there is epidemiological evidence that increased dietary fat intake may reduce the risk 
of developing the disease (Okamoto et al. 2007; Veldink et al. 2007; Morozova et al. 2008). 
Furthermore, a ketogenic diet (60% fat, 20% carbohydrate, 20% protein) in mutant mouse model 
demonstrated an improvement in motor functions and an increase in ATP production from 
mitochondria purified from spinal cord when treated with β-hydroxybutyrate; a supplementation 
of a ketone bodies precursor (caprylic acid) improved mitochondrial function and motor neuron 
count in ALS mouse model (Zhao et al. 2006; Zhao et al. 2012). The probable involvement of 
mitochondria in ALS makes the ketogenic diet (KD) a promising tool for the treatment of the disease; 
furthermore, it is an actual tool to manage pharmacoresistent epilepsy. Ketone bodies indeed, are 
able to act on mitochondrial function by restoring, for example, complex I function (Tieu et al. 2003). 
Ari and colleagues compared standard and ketogenic diets, both with and without adding key 
supplements from the Deanna Protocol (DP) in SOD1 mutant mice (Ari et al. 2014). The DP is 
comprised primarily of arginine alpha-ketoglutarate (AAKG), and includes several other agents that 
were reported to preserve metabolic function and prevent glutamate excitotoxicity. Their data 
demonstrated significant improvements and prolonged longevity in animals fed both the 
supplemented diets compared with the non-supplemented diets (Bedlack et al. 2015). Thus despite 
having a promising potential, in the lack of clinical trials at this time, ALSUntangled group does not 
recommend the Deanna Protocol to patients with ALS (ALSUntangled Group 2013). 
However, all these data must still be translated in human patients. Only Silva et al. tested 
oral supplementation with milk whey proteins and modified starch in a small study of 16 subjects 
treated for 4 months; they demonstrated modest weight gain in the supplement arm while the 
controls continued to lose weight. Intriguingly, the supplement arm appeared to have a slower rate 
of decline in the Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (Silva et al. 2010). 
At present only one trial (NCT01016522) was performed to assess safety and tolerability of KD in 
ALS patients, but results are not yet published. 
Given the complexity of the disease a multi-targeting approach could be extremely 
beneficial. At present, studies on the administration of a high Calorie Energy supplemented Diet 
(CED) together with low doses of the novel multifunctional monoamine oxidase (MAO) 
 
 
inhibitor/iron-chelating compound (M30) are being performed in the SOD1-G93A transgenic mouse 
model, showing promising results. The treatment increased mutant mice survival and produced 
additive neuroprotective effects on motor performance, together with the preservation of 
neuromuscular junction and myofibril regular morphology. Furthermore, it upregulated the 
mitochondrial biogenesis master regulators, metabolic genes and proteins such as PPARγ, UCP1/3, 
NRF1/2, Tfam, and ERRα in gastrocnemius muscle. Effects on gene regulation have been showed 
also in the frontal cortex with elevated levels of Bcl-2 and neurotrophic factors (Golko-Perez et al. 
2016a; Golko-Perez et al. 2016b; Golko-Perez et al. 2016c). This joint approach that targets two 
different disease mechanisms could enhance the neuroprotective effects and is strongly supported 
by the results of this work. 
An emerging nutritional issue relating to ALS specifically and neuromuscular diseases in 
general is the use of nutraceuticals and functional foods. In relation to metal homeostasis 
management, this could be a promising approach instead of the administration of a chelating 
therapy, commonly used in the case of metal poisoning and that has the potential to be harmful 
since it is not intended for long-term use. 
An interesting alternative approach proposed by Bisanz et al., is the development of a probiotic 
supplemented yogurt with food-grade microbes, such as lactic acid bacteria (in particular 
Lactobacillus rhamnosus strain GR-1), known to have an affinity for many toxic metals and pollutants 
(Pb and Cd in vitro and Hg, As and pesticides in vivo), probably due to a mechanism of passive 
sequestration, but also thanks to specific pathways for detoxification. In a pilot study, the Authors, 
demonstrated the value of long-term probiotic based intervention to counter arsenic and mercury 
in pregnant women environmentally and dietary exposed to high levels of heavy metals (Bisanz et 
al. 2014). 
Song et al. instead, developed a yogurt enriched with galacto-oligosaccharides (GOS), a 
prebiotic able to improve the absorption and synthesis of B Vitamins. Its administration to a mouse 
model of ALS led to a delay in symptoms onset and a prolonged lifespan, it attenuated motor neuron 
loss and improved the muscular atrophy and myocyte mitochondrial activity; the treatment 
suppressed the activation of astrocytes and microglia by regulating several inflammatory- and 
apoptosis-related factors. (Song et al. 2013). The development of functional enriched yogurts seems 
to be promising and have the potential to be easily administered to ALS patients at every stage of 
disease, given its soft texture. 
 
 
Among alternative approaches aimed at managing the disease, great attention has been 
given to natural food constituents and herbal compounds, as excellently reviewed by Zhang et al. 
(Zhang et al. 2014). Among these compounds, catechins (epigallocatechin, epicatechin, and 
epicatichin-3-gallate) are the most interesting polyphenolic flavonoids with antioxidant, metal 
chelating and protective properties toward glutamatergic excitotoxicity; they are able to cross the 
blood-brain barrier, to be incorporated in brain tissues and to modulate mitochondrial responses to 
oxidative insults. Catechins are found in high concentrations in some plants, fruits, and vegetables 
and are considered the healthy constituents of green tea, blue berries, cocoa, prune juice, red wine, 
and Ginkgo biloba (Bedlack et al. 2015). Studies in Parkinson’s and Alzheimer’s disease showed 
promising results but, none have been completed in ALS (Chan et al. 2016). However, experiments 
in ALS mouse model support the neuroprotective potential of catechins. In vitro studies showed 
that epicatichin-3-gallate reduced hyperexcitability in SOD1 motor neurons and had a rescue effect 
in motor neurons exposed to H2O2 (Xu et al. 2006). Further investigations in the ALS mouse model, 
showed that presymptomatic oral administration of epicatichin-3-gallate significantly delayed the 
onset of disease and extended the life span. In addition, the treated mice had an increased number 
of motor neurons, diminished microglial activation and a better inflammatory profile (Koh et al. 
2006; Yu et al. 2010). 
These results support the assumption that the use of combined dietary interventions to treat 
ALS have the potential to be a new, simple, low-cost and low-risk approach to impact disease 
progression. Furthermore, it will also contribute to the better understanding of disease 
mechanisms. It is possible that different diet interventions could have additive effects in ALS, and 
combined interventions should be tested together in Phase III trials. 
  
 
 
CONCLUSIONS 
 A multidisciplinary approach to study a limited cohort of sporadic Amyotrophic Lateral Sclerosis 
patients is presented in this work, in contrast with the trendy studies where wide cohorts of 
heterogeneous subjects are pooled together. The detection of clusters of ALS patients is often 
limited to an epidemiological description; here instead, the common environmental exposure 
and the limited number of subjects are exploited to dissect different aspects of the disease. 
Multidisciplinary studies on small cohorts of ALS patients are, at present, very rare. It would be 
of outstanding value to integrate different fields of knowledge, to create a picture of the several 
factors involved in the disease etiology and course, complete as much as possible. This 
approach resulted valuable since results reported are concordant with published data obtained 
in other studies. 
 In this study is reported the first description of the serum proteome of ALS patients with 2DE, 
that allowed to identify a great number of proteins as potentially associated to the disease, not 
only with the aim of deeply investigating the factors involved in the disease, but also in order 
to assess potential biomarkers for disease progression. 
 While the involvement of APR proteins is probably secondary to the compromised status of 
patients, the described deregulation of lipid homeostasis proteins seems to be more directly 
linked in modulating the disease progression, as supported from literature data. 
 From the results obtained in this study, some metals appear to be involved in the disease, 
possibly secondary to the environmental influence, in an area restricted and close to a mine. 
Future assessments on soil and water pollution are strongly recommended. The investigation 
of ALS prevalence in other cohorts of subjects living in similar conditions would be very useful 
in order to confirm results and expand this research and to elucidate the effective role of metals 
in ALS. 
 Great amount of data is, nowadays, a limit in understanding results of experiments performed 
with more and more sophisticated technologies, especially in complex diseases such as ALS. The 
application of new statistical analyses, based on machine learning, where data are the basis of 
the creation of models to interpret interactions among variables, would be the key to translate 
raw data into understandable models. 
 
 
 The lack of an effective pharmacological treatment in ALS leads to rapidly looking for alternative 
approaches to modulate this devastating disease. To this purpose, a nutritional intervention, 
with the development of specific nutritional formulas, would be an effective tool to intervene 
on the patients’ lipid profile and to contrast potential metal’s homeostasis impairment. Thus, 
development of such formulations is strongly supported from the evidences raised from this 
study, together with its application in clinical trials.  
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PRODUCTS 
ABSTRACTS 
 XIX Workshop on the Developments in the Italian PhD Research on Food Science, Technology 
and Biotechnology – 24-26 September 2014 
Micronutrients in a neurodegenerative disorder such as amyotrophic lateral sclerosis  
Stefano De Benedetti 
DeFENS - Department of Food, Environmental and Nutritional Sciences, University of Milan, Italy 
This PhD thesis research project is aimed at investigating the role of micronutrients in Amyotrophic 
Lateral Scelrosis. Their levels will be correlated with the disease status to evaluate how micronutrients 
and their regulatory pathways could influence the manifestation and the difference of clinical signs of 
disease in pre-symptomatic subjects thus explaining the wide phenotypic spectrum of disease. This will 
be performed through different approaches: clinical, biochemical and genetic in order to obtain a 
nutritional outcome. This could help to elucidate the role of micronutrients and its metabolism in the 
pathogenesis and/or in the progression of ALS. 
 IUBMB Symposium FeS 2015 - Iron Sulfur Cluster Biogenesis and Regulation - 23-26 June 2015 
Metals analysis in a small cohort of ALS patients originating from a restricted geographical area: 
preliminary data 
S. De Benedetti1*, G. Lucchini2, A. Marocchi4, S. Penco4, S. Iametti1, E. Gianazza3, F. Bonomi1 
1DeFENS, 2DISAA, 3DISFB, University of Milan, 4Department of Laboratory Medicine, Medical Genetics, 
Niguarda Ca' Granda Hospital, Milan, Italy. 
Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disorder characterized by selective 
degeneration of both upper and lower motor neurons in the brain, brainstem, and spinal cord. This 
results in paralysis due to muscle weakness and atrophy, leading to death in 3-5 years since the first 
manifestations of symptoms. Genetic and environmental factors are involved in the pathogenesis of the 
disease and metals metabolism have been linked to ALS. Transition metal induced toxicity (including 
iron toxicity) has been proposed to be involved in ALS and higher concentrations of metals and proteins 
that regulate metal homeostasis have been described in ALS patients. Thiophylic metals have been 
shown to be capable of displacing iron from reduced FeS proteins, that thus may represent a yet 
underexplored target in this frame. We evaluated the concentration of different metals in both serum 
and urine by ICP-MS, in a cohort of subjects with diagnosis of ALS, originating from a restricted 
geographical area where the incidence of ALS is above average. Principal Component Analysis (PCA) 
showed higher concentrations of metals in ALS subjects, especially in urine. The only exception is for As, 
where lower levels have been found in ALS patients, particularly in serum samples. Artificial Neural 
Networks analysis was able to discriminate between subjects and controls, linking to the disease lower 
levels of As and higher levels of Ni. These data give an insight to the status of metals in these patients 
that, despite being few subjects, they share a common environmental exposure.  
  
 
 
 XX Workshop on the Developments in the Italian PhD Research on Food Science, Technology 
and Biotechnology – 23-25 September 2015 
Metals and proteomics of the biological fluids in ALS patients: Preliminary data 
Stefano De Benedetti  
DeFENS - Department of Food, Environmental and Nutritional Sciences, University of Milan, Italy 
Biochemical analyses described in the PhD dissertation project were performed on a small cohort of 
subjects affected by sporadic ALS, all originating from a restricted geographical area. In detail, serum 
and urine levels of a customized panel of metals were measured; proteomic analyses were performed 
on urine by SDS-PAGE and on serum by 2D-Electrophoresis. Data collected through a survey on lifestyle 
and nutrition were analyzed by Artificial Neural Networks. 
 XVIII CONGRESSO NAZIONALE SIGU – Società Italiana di Genetica Umana – 22-23 October 
2015 
Valutazione delle concentrazioni di metalli in pazienti affetti da Sclerosi Laterale Amiotrofica 
geneticamente caratterizzati 
S. De Benedetti1,4, G. Lucchini2, A. Marocchi4, C. Lunetta5, S. Iametti1, E. Gianazza3, F. Bonomi1, S. Penco4. 
1DeFENS, 2DISAA, 3DISFB, Università degli Studi di Milano, 4Dipartimento di Medicina di Laboratorio, 
Genetica Medica, Ospedale Niguarda Ca' Granda , Milano, 5NEuroMuscular Omnicentre (NEMO), 
Fondazione Serena Onlus, Ospedale Niguarda Ca' Granda, Milano. 
La Sclerosi Laterale Amiotrofica (SLA) è una malattia neurodegenerativa rara caratterizzata da paralisi 
muscolare progressiva conseguente alla degenerazione dei motoneuroni nella corteccia motoria 
primitiva, nei tratti corticospinali, nel tronco cerebrale e nel midollo spinale.  
La SLA ha un'incidenza di 2.1 casi ogni 100˙000 individui all'anno e una prevalenza stimata di 5.4/100.000 
casi, principalmente sporadica; le forme familiari sono circa il 5-10% del totale. Le cause della malattia 
sono al momento ignote. L’ipotesi attualmente accreditata è che si tratti di una patologia multifattoriale, 
per cui vari fattori ambientali concorrerebbero a determinare i sintomi della malattia in individui con 
una suscettibilità genetica di base, verosimilmente poligenica. Fino a ora sono stati individuati numerosi 
geni causativi tra cui quelli di maggiore rilevanza sono attualmente SOD1, FUS, TARDBP e C9ORF72. E’ 
stato proposto che la tossicità indotta dai metalli di transizione possa essere coinvolta nella patologia e 
alte concentrazioni di metalli e proteine che regolano la loro omeostasi sono state descritte nei pazienti 
con SLA. In questo studio, è stato preso in esame un piccolo gruppo di pazienti (n=7) con diagnosi di SLA, 
provenienti da una ristretta area geografica della Liguria, che quindi condividono la stessa esposizione a 
fattori ambientali. I principali geni coinvolti nella malattia sono stati analizzati su DNA estratto da sangue 
periferico mediante sequenziamento diretto (SOD1, FUS, TARDBP) e Repeated Primer PCR (C9ORF72). 
Tutti i pazienti sono risultati negativi all’analisi genetica. Il siero dei pazienti è stato sottoposto all’analisi 
con ICP-MS per valutare le concentrazioni di diversi metalli (Fe, Zn, Se, Sr, Cd, Pb, Ni, Cu, Cr, As). I livelli 
di Ni e Pb sono risultati più alti nei pazienti rispetto a un gruppo di controlli sani (n=5) confrontabili per 
età e provenienti dalla stessa area geografica, viceversa per i livelli di As. Attualmente sono in corso sui 
sieri analisi di metalli più rari (Mn, Al, Co, V, U, Mo, Ag, Sn) e indagini di proteomica con Elettroforesi 2-
D. Questo approccio permetterà di valutare l’influenza di uno dei fattori ambientali il cui coinvolgimento 
nella SLA è da lungo ipotizzato. 
  
 
 
 Riunione dei giovani biochimici dell’area Milanese – 20-22 March 2016 
Metallomics and proteomics of the biological fluids in ALS patients: preliminary data 
Stefano De Benedetti1, Giorgio Lucchini2, Alessandro Marocchi3, Silvana Penco3, Christian Lunetta4, 
Stefania Iametti1, Elisabetta Gianazza5, Francesco Bonomi1 
1DeFENS, 2DiSAA, 5DiSFeB - University of Milan, 20133, Milano. 3Medical Genetics Unit, Department of 
Laboratory Medicine, 4NEuroMuscular Omnicentre (NEMO), Fondazione Serena Onlus - Niguarda Ca' 
Granda Hospital, 20169, Milano 
Introduction. Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disorder characterized by 
selective degeneration of both upper and lower motor neurons in the brain, brainstem, and spinal cord. 
This results in paralysis due to muscle weakness and atrophy, leading to death in 3-5 years. Genetic and 
environmental factors are involved in the pathogenesis of the disease and metals metabolism have been 
linked to ALS. 
Methods. The study enrolled 7 patients and 5 controls (age matched, living in the same geographical 
area). For metal quantitation, samples were analyzed by ICP-MS. For proteomic analyses, immobilized 
pH gradient covered the 4-10 pH range. Image analyses were carried out with Image Master Software. 
Statistical analyses were carried out with Student’s t-test. 
Results. Among the 20 metals analyzed, As concentration resulted significantly lower in patients than in 
controls (p=0.007); Hg also was found in lower concentration in patients, but with a lower statistical 
significance (p=0.13). Higher concentration of Al in patients was detected (p=0.08). In this study, we 
were not able to confirm the higher concentrations of Ni and Pb in patients previously described in a 
smaller cohort. Our proteomics data show that APOA2 is decreased by 30% in patients with respect to 
controls. Furthermore, AHSG and SAP showed a significant decrease in patients with a story of more 
than 10 years of disease. 
Conclusions. Impaired metal homeostasis, attributable to environmental exposure, could lead to 
mineral overload. Besides promoting oxidative stress, metals can compete for the binding sites of metal-
containing proteins, such as those containing iron-sulfur clusters3. At present, no literature data link 
APOA2 to ALS, but the fact that its mRNA is processed by TDP43, provides a possible connection with 
the disease. The proteins differentially expressed belong to the group of Acute Phase Reaction proteins, 
possibly linking ALS to a chronic inflammation status. 
 ENCALS Meeting 2016 – 19-21 May 2016 
Metal and proteomic analysis of sporadic ALS patients with common geographical origin  
S. De Benedetti 1, G. Lucchini 2, A. Marocchi 3, S. Penco 3, C. Lunetta 4, S. Iametti 1, E. Gianazza 5, F. Bonomi 
1  
1 DeFENS, 2 DiSAA, 5 DiSFeB - University of Milan, 3 Medical Genetics Unit, Department of Laboratory 
Medicine, 4 NEuroMuscular Omnicentre (NEMO), Fondazione Serena Onlus - Niguarda Ca' Granda 
Hospital, Milan  
Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disorder characterized by selective 
degeneration of both upper and lower motor neurons in the brain, brainstem, and spinal cord. This 
results in paralysis due to muscle weakness and atrophy, leading to death in 3-5 years. Genetic and 
environmental factors are involved in the pathogenesis of the disease and metals metabolism have been 
linked to ALS. This study enrolled seven patients and five controls (age matched, living in the same 
geographical area). For metal quantitation, samples of serum were analyzed by ICP-MS. For proteomic 
analyses, immobilized pH gradient covered the 4-10 and 3- 7 pH range. Statistical analyses were carried 
out with Student's t-test and Artificial Neural Networks. Among the metals analyzed, As concentration 
resulted significantly lower in patients than in controls (p=0.007); Hg too was found in lower 
concentration in patients, but with a lower statistical significance (p=0.13). Higher concentration of Al in 
patients was detected (p=0.08). In this study, we were not able to confirm the higher concentrations of 
 
 
Ni and Pb in patients previously described in a smaller cohort. Our proteomics data show that APOA2 is 
decreased by 30% in patients with respect to controls. Furthermore, AHSG and SAP showed a significant 
decrease in patients with a story of more than 10 years of disease. Impaired metal homeostasis, 
attributable to environmental exposure, could lead to mineral overload. Besides promoting oxidative 
stress, metals can compete for the binding sites of metalcontaining proteins, such as those containing 
iron-sulfur clusters. At present, no literature data link APOA2 to ALS, but the fact that its mRNA is 
processed by TDP43, provides a possible connection with the disease. The proteins differentially 
expressed belong to the group of Acute Phase Reaction proteins, possibly linking ALS to a chronic 
inflammation status. Further experiments are still ongoing. 
 FEBS/IUBMB Advanced Lecture Course "Molecular basis of human diseases: 50 years 
anniversary of Spetses summer schools" – 27th May-1st June 2016 
Serum metal concentrations and proteomics of ALS patients originating from a small geographical 
area 
Stefano De Benedetti, Giorgio Lucchini, Alessandro Marocchi, Silvana Penco, Christian Lunetta, Stefania 
Iametti, Elisabetta Gianazza, Francesco Bonomi 
Department of Food, Environmental and Nutritional Sciences – University of Milan - Italy 
Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disorder characterized by selective 
degeneration of both upper and lower motor neurons in the brain, brainstem, and spinal cord. This 
results in paralysis due to muscle weakness and atrophy, leading to death in 3-5 years. Genetic and 
environmental factors are involved in the pathogenesis of the disease and metals metabolism have been 
linked to ALS. This study enrolled seven patients and five controls (age matched, living in the same 
geographical area). For metal quantitation, samples of serum were analyzed by ICP-MS. For proteomic 
analyses, immobilized pH gradient covered the 4-10 and 3-7 pH range. Statistical analyses were carried 
out with Student’s t-test and Artificial Neural Networks. Among the 20 metals analyzed, As 
concentration resulted significantly lower in patients than in controls (p=0.007); Hg too was found in 
lower concentration in patients, but with a lower statistical significance (p=0.13). Higher concentration 
of Al in patients was detected (p=0.08). In this study, we were not able to confirm the higher 
concentrations of Ni and Pb in patients previously described in a smaller cohort3. Our proteomics data 
show that APOA2 is decreased by 30% in patients with respect to controls. Furthermore, AHSG and SAP 
showed a significant decrease in patients with a story of more than 10 years of disease. Impaired metal 
homeostasis, attributable to environmental exposure, could lead to mineral overload. Besides 
promoting oxidative stress, metals can compete for the binding sites of metal-containing proteins, such 
as those containing iron-sulfur clusters. At present, no literature data link APOA2 to ALS, but the fact 
that its mRNA is processed by TDP43, provides a possible connection with the disease. The proteins 
differentially expressed belong to the group of Acute Phase Reaction proteins, possibly linking ALS to a 
chronic inflammation status. Further experiments are still ongoing. 
 XXI Workshop on the Developments in the Italian PhD Research on Food Science, Technology 
and Biotechnology – 14-16 September 2016 
Sporadic Amyotrophic Lateral Sclerosis in patients with common geographical origin: a multidisciplinary study. 
Stefano De Benedetti  
DeFENS - Department of Food, Environmental and Nutritional Sciences, University of Milan, Italy 
Amyotrophic Lateral Sclerosis, a fatal neurodegenerative disorder, is object of intensive research since the causes are 
still unknown and a treatment still lacks. Thanks to the recent technological improvements, the current trend of 
studies on this pathology points toward the analysis of huge groups of patients, in the search of new causative genes 
or diagnostic biomarkers. Being a rare disease however, to recruit a big number of patients, is necessary to analyze 
simultaneously subjects originating from completely different areas, thus losing the chance to evaluate patients with 
a common environmental exposure. This PhD project is aimed to study a small cohort of ALS subjects originating 
 
 
from a restricted geographical area, with a multidisciplinary approach spanning from genetics to proteomics, to 
nutrition. 
 XIV Congresso FISV – Federazione Italiana Scienze della Vita – 20-23 September 2016 
A multidisciplinary approach to study Sporadic Amyotrophic Lateral Sclerosis in patients with common 
geographical origin. 
S. De Benedetti1, G. Lucchini2, A. Marocchi3, S. Penco3, C. Lunetta4, S. Iametti1, E. Gianazza5, F. Bonomi1 
1 DeFENS, 2 DiSAA, 5 DiSFeB - University of Milan, 3 Medical Genetics Unit, Department of Laboratory 
Medicine, 4 NEuroMuscular Omnicentre (NEMO), Fondazione Serena Onlus - Niguarda Ca’ Granda 
Hospital 
Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disorder, is object of intensive research 
as the causes are still unknown and a treatment not available yet. This project is aimed to study, with a 
multidisciplinary approach, a small cohort of ALS subjects with a common environmental exposure. For 
metal quantitation, samples of serum and whole blood were analyzed by ICP-MS. For proteomic 
analyses, immobilized pH gradient covered the 4-10 and 3-7 pH range. 
Arsenic concentration resulted significantly lower in patients than in controls. Also, Mn and Hg showed 
lower levels in patients. Levels of plasma APOA2 protein resulted decreased in patients with respect to 
controls, whereas SAMP showed a significant decrease only in the late onset group. APOA1 and TTHY 
also were decreased, the latter in late-onset patients. RET4 was decreased only in the early-onset group. 
When evaluating APOE genotype we found a 3-fold increase in the frequency of E3/E4 genotype in the 
patient’s group. DNA oxidative stress has been evaluated through a Comet Assay. The multidisciplinary 
approach applied in this study allowed to dissect different aspects of ALS, often are evaluated separately 
and in heterogeneous cohorts of patients. 
 27th International Symposium on ALS/MND – 6-9 December 2016 
A multidisciplinary study of sALS in patients originating from a restricted geographical area. 
Stefano De Benedetti, Giorgio Lucchini, Alessandro Marocchi, Silvana Penco, Christian Lunetta, 
Stefania Iametti, Elisabetta Gianazza, Francesco Bonomi 
Department of Food, Environmental and Nutritional Sciences – University of Milan - Italy 
Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disorder characterized by selective 
degeneration of both upper and lower motor neurons in the brain, brainstem, and spinal cord. This 
results in paralysis due to muscle weakness and atrophy, leading to death in 3-5 years. Genetic and 
environmental factors are involved in the pathogenesis of this disease and metals metabolism has been 
linked to ALS. Proteomic studies are currently being performed to search for possible biomarkers. Here 
we present a study aimed at investigating different aspects of the disease, based on a multidisciplinary 
approach. The cohort of ALS patients that we analyzed includes seven patients, all originating from a 
common, restricted, geographical area and five matched controls. Environmental exposure is the same 
for all these subjects. SOD1, FUS, TDP43, C9ORF72 and APOE genotypes were evaluated. For metal 
quantitation, samples of serum and whole blood were analyzed by ICP-MS. For proteomic analyses, 
immobilized pH gradient covered the 4-10 and 3-7 pH range both in reducing and non-reducing 
conditions. Levels of DNA oxidation were evaluated by a comet assay. Statistical analyses were carried 
out with Student’s t-test and Artificial Neural Networks. Among the metals analyzed in serum, As 
concentration resulted significantly lower in patients than in controls (p=0.007); Mn and Hg showed 
lower levels in patients. Auto-CM analysis linked closely high concentrations of Al and Se to the ALS 
group. Levels of metals in whole blood have been correlated with levels in serum. Our proteomics data 
show that some proteins related to Acute Phase Response (APR) and lipid homeostasis are decreased in 
patients (APOA1, APOA2, TTR, RET4 and SAP) while only ANT3 results increased. For some of these 
proteins we can describe a drastic reduction in the first 5 years of disease. Apoε4 allele is more 
represented in the patient’s group than in controls’. Impaired metal homeostasis, attributable to 
 
 
environmental exposure, could lead to mineral overload. Waters of the creek of the narrow valley where 
these subjects are located, are reported to be strongly polluted due to Acid Mine Drainage. Besides 
promoting oxidative stress, metals can compete for the binding sites of metal-containing proteins, such 
as those containing iron-sulfur clusters. The different expression of the APR proteins reported could be 
a reflection of the disease status of the subjects analyzed, possibly linking ALS to a chronic inflammation 
status. Enrichment in Apoε4 allele frequency in patients may provide a link between neurodegeneration 
and lipid metabolism disturbances. It is important to highlight the fact that all the proteins found 
differentially expressed in our study have already been described in other studies. This strengthens our 
methodological approach, based on a small number of patients but with a common environmental 
exposure. 
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